

Article

Synthesis of Four Orthogonally Protected Rare L-Hexose Thioglycosides from D-Mannose by C-5 and C-4 Epimerization

 Fruzsina Demeter ¹, Ilona Bereczki ¹ , Anikó Borbás ^{1,*}  and Mihály Herczeg ^{1,2,*} 
¹ Department of Pharmaceutical Chemistry, University of Debrecen, Egyetem tér 1, H-4032 Debrecen, Hungary; demeter.fruzsina@science.unideb.hu (F.D.); bereczki.ilona@pharm.unideb.hu (I.B.)

² Research Group for Oligosaccharide Chemistry of Hungarian Academy of Sciences, ELKH, Egyetem tér 1, H-4032 Debrecen, Hungary

* Correspondence: borbas.aniko@pharm.unideb.hu (A.B.); herczeg.mihaly@pharm.unideb.hu (M.H.); Tel.: +36-52-512-900 (ext. 22472) (M.H.)

Abstract: L-Hexoses are important components of biologically relevant compounds and precursors of some therapeutics. However, they typically cannot be obtained from natural sources and due to the complexity of their synthesis, their commercially available derivatives are also very expensive. Starting from one of the cheapest D-hexoses, D-mannose, using inexpensive and readily available chemicals, we developed a reaction pathway to obtain two orthogonally protected L-hexose thioglycoside derivatives, L-gulose and L-galactose, through the corresponding 5,6-unsaturated thioglycosides by C-5 epimerization. From these derivatives, the orthogonally protected thioglycosides of further two L-hexoses (L-allose and L-glucose) were synthesized by C-4 epimerization. The preparation of the key intermediates, the 5,6-unsaturated derivatives, was systematically studied using various protecting groups. By the method developed, we are able to produce highly functionalized L-gulose derivatives in 9 steps (total yields: 21–23%) and L-galactose derivatives in 12 steps (total yields: 6–8%) starting from D-mannose.

Keywords: L-hexoses; thioglycosides; epimerization; elimination; hydroboration



Citation: Demeter, F.; Bereczki, I.; Borbás, A.; Herczeg, M. Synthesis of Four Orthogonally Protected Rare L-Hexose Thioglycosides from D-Mannose by C-5 and C-4 Epimerization. *Molecules* **2022**, *27*, 3422. <https://doi.org/10.3390/molecules27113422>

Academic Editor: Alberto Marra

Received: 4 May 2022

Accepted: 20 May 2022

Published: 25 May 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

L-Sugars are key constituents of many biorelevant natural products such as polysaccharides, glycopeptides, and terpene or steroid glycosides (Figure 1) [1]. For example, L-guluronic acid is found in alginates (I) [2–6], the cell walls polysaccharides of brown algae, and L-gulose is a component of the potent antitumor antibiotic Bleomycin A2 (II) produced by *Streptomyces verticillus* [7–9]. The tetracyclic triterpene Datiscoside C (III), which is isolated from *Datisca glomerata*, contains a 6-deoxy-L-alloside [10], while L-galactose can be found in the A side chain of the pectic polysaccharide rhamnogalacturonan II (IV) [11]. L-Glucose is a major component of littoralisone isolated from *Verbena littoralis*, which has a nerve growth factor potentiating activity [12,13]. Apoptolidine A (V) macrolide antibiotic, isolated from *Nocardioopsis* species and used to initiate selective apoptosis of tumor cells, contains a 6-deoxy-L-glucose [14–16]. Furthermore, L-iduronic acid is a key component of the important mammalian glycosaminoglycans heparin, heparan sulfate, and dermatan sulfate [17–19].

L-Hexoses are rare sugars, much less common in nature than their enantiomers, the D-hexoses, and are thus very expensive [20], which prevents the exploitation of their biological potential. Therefore, it is important to produce L-sugars from common carbohydrates by cost-effective and high-yielding synthetic routes. To meet the demand of L-sugars, various strategies have been developed for their synthesis [20–24], including C-5 epimerization of readily available D-sugars [25–37], homologation of carbohydrates with shorter chains [38–42], de novo synthetic routes [43–50], head to tail inversion [51–56], site selective epimerization [57,58], C-H activation [59,60], and enzymatic synthesis [61,62]. However,

there are very few approaches that provide the L-sugars as glycosyl donors, e.g., in form of thioglycosides, ready for glycosylation [60,63–66]. Thus, it is highly desirable to develop new methods to produce rare sugars directly in the form of functionalized glycosyl donors suitable for oligosaccharide synthesis.





Figure 1. Structure of some L-hexose containing natural compounds.

Herein, we present the synthesis of four L-sugars, the L-gulose, -allose, -galactose, and -glucose, as their highly functionalized thioglycosides from a cheaply accessible D-mannosyl thioglycoside, using the elimination-hydroboration-oxidation-based C-5 epimerization as the key transformation. The synthesis of L-sugars by hydroboration/oxidation of D-sugar-derived 5-enopyranosides has been extensively studied on α -O-glycosides, focusing mainly on D-glucosides, and to a lesser extent also on sugars of other configurations. (Scheme 1A) [25,26,67]. Recently, we have successfully extended the scope of this method to thioglycosides derived from D-glucose, thus giving direct, rapid access to L-idose glycosyl donors. (Scheme 1B) [65,66]. We demonstrated that the α -anomeric configuration is crucial and the bulky C-4 substituent is advantageous for the high L-*ido* selectivity and that, despite the sensitivity of sulfur to oxidation, the over-oxidation into sulfoxide is negligible [65,66]. On the basis of these results, we envisioned the expeditious synthesis of L-gulose and L-galactose donors starting from D-mannosyl and D-altrosyl thioglycosides, which are readily accessible from one of the cheapest sugars, D-mannose. Subsequent protecting group manipulation and stereoselective C-4 epimerization by either the Mitsunobu reaction or oxidation/stereoselective reduction were planned to obtain L-allose and L-glucose in the form of their thioglycosides (Scheme 1C).



Scheme 1. Literature results on C-5 epimerization of O- and S-glycosides by using elimination-hydroboration-oxidation ((A) [25,26,67]; (B) [65,66].), and planned synthetic route to orthogonally protected L-gulo-, allo-, galacto-, and glucopyranosyl thioglycosides from D-mannose (C).


The most common anomeric leaving group, thiophenyl, was chosen as the aglycone, and the incorporation of ether and ester protecting groups (that are non-participating and participating groups) into the C-2 position was also devised to make the resulting L-thioglycosides suitable for the synthesis of either α - or β -glycosides. Our synthetic

design requires 5,6-unsaturated pyranosides as key intermediates on which hydroboration/oxidation can be performed. A well-documented method for preparing the pyranosyl exocyclic alkene is the base-mediated elimination of the corresponding 6-deoxy-6-iodoglycosides, for which silver(I) fluoride (AgF) [68], potassium *tert*-butoxide (*t*-BuOK) [69], sodium hydride (NaH) [70], and 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU) [71–74] reagents are the most commonly used. However, monitoring of this dehydroiodination step is notoriously difficult, and it often suffers from unwanted side reactions [65,66] that may be exacerbated in the presence of base-sensitive ester protecting groups. Therefore, special attention was paid to optimizing this elimination step to make the whole synthetic procedure reliable and efficient.

While the hydroboration of D-glucoside-derived enopyranosides has been studied extensively [25,26,75–77], only two publications have so far addressed the hydroboration of the corresponding mannosides [25,67]. The $\text{BH}_3\cdot\text{THF}$ -mediated C-5 epimerization of 5-enomannoside **8** was reported to proceed with moderate diastereoselectivity [25], probably due to the steric hindrance by the C-2 substituent which hampers attack of the reagent from the β -face (Scheme 1A). A much higher *L-gulo*:*D-manno* ratio could be achieved using catecholborane and $\text{RhCl}(\text{PPh}_3)_3$ catalysis (Wilkinson's catalyst), but the protecting group pattern of mannoside alkenes also proved to be an important factor in *L-gulo* selectivity (**11**→**12**) [67]. As our goal was to produce highly functionalized, orthogonally protected thioglycoside donors via cost-effective routes, we focused on exploiting the stereoselectivity-enhancing effects of the different protecting groups and tried to avoid the use of expensive metal catalysts.

2. Results

First, the two key transformations, elimination and hydroboration/oxidation, were tested on the ether protected derivative **25**, which was obtained from the known phenyl 1-thio- α -D-mannoside derivative **23** [78,79] (Scheme 2). Regioselective reductive 4,6-acetal opening of compound **23** gave the primary alcohol **24**, treatment of which with Ph_3P , iodine, and imidazole afforded the 6-iodo-mannoside **25**. For the next dehydroiodination reaction, our choice was DBU as a commonly used elimination reagent, which is compatible with both ester and ether protecting groups.



Scheme 2. Preparation of the 5,6-unsaturated **26** from SPh- α -D-mannopyranoside and its conversion to L-gulose series by hydroboration/oxidation.

Treatment of **25** with DBU (4 equiv.) in dry THF at reflux temperature (70 °C) for 5 h gave the expected unsaturated product **26**, however, only with moderate yield (43%) due to the incomplete conversion of **25** and formation of by-product **27** (Table 1). The latter sugar-amidinium salt, which results from a nucleophilic substitution of iodine **25** by DBU, is quite an unusual product. Bicyclic amidine DBU features poor nucleophilicity and strong basicity [80–82], and although there are an increasing number of examples of it reacting as a nucleophilic agent [83–85], this behavior has so far not been observed

in HI elimination reactions. At the same time, similar 6-deoxy-6-ammonium salts of carbohydrates have already been prepared, which have been investigated as chiral ionic liquids [86] or antibacterial agents [87,88], however, they do not contain the DBU but the remarkably more nucleophilic DABCO (1,4-diazabicyclo[2.2.2]octane) at the primary position of pyranosides.

Table 1. Optimization of the DBU mediated elimination reaction of **25**.

Solvent	Reagent	Temperature (°C)	Time (h)	Yield (%)
THF	DBU (4 equiv.)	70	5 [a]	26 : 43 27 : 12 [a]
Toluene	DBU (4 equiv.)	110	2	26 : 40 27 : 22
THF	DBU (4 equiv.)	70	24	26 : 53 27 : 28


[a] Remaining **25** was detected by TLC but was not isolated.

In order to improve the yield of **26**, the elimination reaction was carried out in dry toluene at elevated temperature (110 °C). After 2 h under reflux, higher conversion of the starting iodide was observed, however, the yield of **26** remained moderate (40%) and the ratio of **27** to **26** increased, indicating that the higher temperature favored the competing nucleophilic substitution rather than elimination. Changing back the solvent to THF and increasing the reaction time to 24 h yielded the expected 5,6-unsaturated derivative with 53% yield, but, unfortunately, the formation of the unwanted DBU-sugar conjugate **27** could not be suppressed.

The C-5 epimerization of **26** was performed by hydroboration with $\text{BH}_3 \cdot \text{THF}$ complex followed by oxidation with H_2O_2 under previously optimized conditions, using 10 equiv. of the borane reagent [25,26,65–67]. Although the yield of the expected L-gulo-configured product **28** was only 53%, a sufficiently high L-guloside: D-mannoside ratio was observed (**28**:**24**~5:1), so it was considered worthwhile to investigate the C-5 epimerization of 1-thiomannoside alkenes having other protecting group patterns.


2.1. Synthesis of L-Gulose and L-Allose Derivatives from D-Mannose

In order to thoroughly investigate the effect of ether and ester protecting groups on the production of L-hexoses, three different substitution patterns were installed on phenyl 1-thio- α -D-mannopyranoside. In each case, (2-naphthyl)methyl ether (NAP) was introduced to the C-4 position. The 2,3-hydroxyl groups, on the other hand, were masked in varying ways, using either di-O-benzyl or di-O-benzoyl or 2-O-benzoyl-3-O-benzyl protection (Scheme 3). First, the 4,6-O-(2-naphthyl)methylene derivative of phenyl α -1-thio-D-mannoside (**29**) [89–91] was prepared from D-mannose, as a suitable starting material, in four steps using routine transformations. On route to the alternating ether–ester protecting group combination, the 3-O-benzyl-protected derivative **30** was formed by preparing the temporary 2,3-O-stannylene acetal derivative using dibutyltin oxide in dry toluene, followed by its reaction with BnBr and CsF. Position C-2 of **30** was esterified with BzCl in dry pyridine to give the expected 2-O-benzoyl-3-O-benzyl protected compound **31**. Alkylation of **29** with BnBr under basic conditions gave the 2,3-di-O-benzyl derivative **32**. The ester groups at positions 2 and 3 of diol **29** were formed with BzCl in dry pyridine to give **33**. In compounds **31**, **32**, and **33**, the primary hydroxyl group was liberated by regioselective reductive ring-opening reaction of the 4,6-acetal with $\text{BH}_3 \cdot \text{THF}/\text{TMSOTf}$ reagent combination in dry dichloromethane. The expected 6-OH derivatives **34**, **35**, and **36** were obtained in excellent yields with complete regioselectivity. Subsequently, the primary alcohols were converted to the 6-iodo derivatives **37**, **38**, and **39** by treatment with triphenylphosphine, iodine, and imidazole. Since the DBU-induced elimination did not work satisfactorily in the model reaction of **25**, the elimination reactions of **37–39** were studied using the three most common dehydrohalogenating reagents: NaH, DBU, and AgF.



Scheme 3. Synthesis of 6-deoxy-6-iodo-D-mannopyranosides.


The NaH induced elimination of the fully ether-protected mannoside **37** resulted in the expected 5,6-unsaturated **40** with an excellent, 91% yield (Scheme 4).



Scheme 4. Elimination reactions of the fully ether-protected *D-manno* derivative **37**.

Treatment of **37** with DBU led to, again, the simultaneous formation of the desired alkene derivative **40** and the 6-amidinium by-product **41** in a ~5:4 ratio. The HI elimination using AgF produced the exocyclic alkene derivative in high efficacy, however, a small amount of the corresponding 6-deoxy-6-fluoro derivative **42** was also obtained due to a concomitant nucleophilic substitution reaction on compound **37**.

The next tested compound was the 2,3-di-*O*-benzoyl derivative **38** (Scheme 5). In the NaH-mediated reaction, instead of the fully protected exocyclic alkene, the unsaturated 2,3-diol **43** was formed since, as expected, the ester groups were cleaved under the used strongly basic conditions. Unfortunately, the yield of **43** was only 17%, and the 3,6-anhydro derivative **44** was isolated as the major product with 59% yield. The predominant formation of **44** in this reaction indicates that the ester-cleavage preceded the elimination reaction and the 6-iodo-2,3-diol intermediate formed rather suffered an intramolecular nucleophilic substitution by the 3-OH than an E2 elimination reaction by NaH.




Scheme 5. Elimination reactions of 2,3-di-*O*-benzoyl *D*-manno derivative **38**.

The DBU-induced elimination reaction gave the expected 5,6-unsaturated compound **45** in good yield (66%). A nucleophilic substitution reaction by DBU was also observed, although to a slightly lesser extent than for the fully ether protected **25** and **37**, resulting in the quaternary amidinium salt **46** in 31% yield.

Dehydroiodination with AgF gave the expected compound **45** in moderate yield of 55%, and a double eliminated derivative (**47**) was isolated as the by-product. Formation of the 3-phenylthio glycal derivative **47** can be explained by elimination of the 3-OBz group followed by an allylic rearrangement reaction of the intermediate 2,3-unsaturated thioglycoside [92].

In the case of the 2-*O*-benzoyl-3-*O*-benzyl protected **39**, only the 2,6-anhydro derivative **48** was formed in the elimination with NaH, in excellent yield (99%) (Scheme 6).




Scheme 6. Elimination reactions of 2-*O*-benzoyl-3-*O*-benzyl *D*-mannopyranoside **39**.

Using DBU as the eliminating agent, the expected unsaturated compound **49** was isolated in moderate yield (54%), and the amidinium by-product (**50**) was formed again in a competitive nucleophilic substitution reaction. For this derivative (**39**), the elimination reaction elicited by AgF gave the best result, the expected exocyclic alkene **49** was obtained in 87% yield and no by-product formation was observed.

After successful preparation of the 5,6-unsaturated derivatives, the C-5 epimerization reactions were performed on all three mannose-derived exocyclic alkenes (Scheme 7). The epimerization process included hydroboration with $\text{BH}_3 \cdot \text{THF}$ complex in dry THF followed by oxidation with 30% H_2O_2 , and hydrolysis of the resulting boronic acid ester under alkaline conditions with satd. NaHCO_3 solution. The conversion of **40**, **45**, and **49** into L-series proceeded with acceptable-to-high stereoselectivity, producing the expected L-gulopyranosides **51**, **52**, and **53** with good to excellent yields. The protecting group patterns noticeably affected both the yield and stereoselectivity of the C-5 epimerization. While only


a 5.4 to 1 *L-gulo*:*D-manno* ratio was obtained with the fully ether protected **40**, the *L-gulo* ratio significantly increased to 9.3:1 by changing the 2,3-benzyl groups into benzoyls in **45**.



Scheme 7. C-5 epimerization of the 5,6-unsaturated derivatives of D-mannoside origin.

The highest yield and the best *L-gulo* selectivity was achieved from **49** having the benzoyl group at position C-2. It is hypothesized that the C-2 ester group delivers the borane to the top face through coordination to the carbonyl group, and this promotes hydride donation from the upper side to the C-5 carbon. The *D-manno* derivatives (**34**, **35**, and **36**) were also isolated from the reaction mixtures which can be recycled and converted to the *L-gulo* configured product in three steps (iodination, elimination, C-5 epimerization).

The *L-gulo* derivatives (**51**, **52**, **53**) were converted to the corresponding L-allopyranosides by oxidation/reduction-based C-4 epimerization in four steps (Scheme 8). First, the (2-naphthyl)methyl group was moved from position 4 to the primary position via a DDQ (2,3-dichloro-5,6-dicyanobenzoquinone) mediated oxidative acetal ring closure under strictly anhydrous conditions followed by a reductive acetal opening with BH₃·Me₃N/AlCl₃ reagent combination of the obtaining **54**, **55**, and **56**.




Scheme 8. C-4 epimerization of the L-gulopyranoside derivatives.

The latter reaction gave the required 4-OH products **57**, **58**, and **59** in a regioselective way with excellent yields. Oxidation of the free hydroxyl groups using pyridinium chlorochromate (PCC) in dry CH₂Cl₂ provided the expected 4-keto derivatives **60**, **61**, and **62** in good yields. The final reductive transformation was performed with L-selectride, because reduction of ulosides with L-selectride [93] at low temperature has been reported to give *cis* vicinal diols with high selectivity [64,94]. Reduction of compounds **60** and **62** with L-selectride occurred, indeed, with high stereoselectivity producing the expected equatorial 4-OH-containing L-allopyranosides **63** and **65** in excellent yields. However, reduction of the 2,3-di-*O*-benzoyl derivative **61** resulted in an inseparable 5:1 mixture of the *L-gulo* (**58**) and *L-allo* (**64**) configured products. The epimeric ratio was determined on the basis of the ¹H NMR spectrum showing the H-3 *L-gulo* signal at 5.75 ppm and H-3 *L-allo* signal at

6.10 ppm. The high *allo*-selectivity in the reduction of **63** and **65** can be explained by the Cram's chelation model [95]. In the present case, the metal coordinates to the carbonyl and O-3, hindering the attack by the reagent from the top-face, thus the hydride attacks from the bottom-face resulting selectively in the *allo*-epimers. The low and opposite stereoselectivity observed in the reduction of **61** was surprising, but literature survey revealed similar examples when no chelate control was observed during the reduction in the presence of an adjacent ester group [64,96,97]. The probable cause is that an ester protected oxygen lacks chelating ability due to the electron-withdrawing properties of the ester group. In the case of **61**, coordination of the metal to O-6 might be possible at the bottom-side, facilitating the attack of the hydride from the upper-side.

2.2. Synthesis of L-Galactose and L-Glucose Derivatives from D-Mannose through D-altrose


After successful conversion of highly functionalized D-mannosides to L-gulopyranosyl and L-allopyranosyl donors, our attention turned to the synthesis of L-galacto and L-gluco derivatives, which is achievable from D-mannose through D-altrose. First, mannoside **29** was converted to the functionalized D-altrose thioglycosides **72** and **73** ready for the elimination reactions (Scheme 9). The C-2 hydroxyl group of diol **29** was selectively protected with a benzoyl group via introduction of a cyclic orthobenzoate to the 2,3-*cis* diol followed by regioselective orthoester opening under acidic conditions to give the axial ester **66** in an acceptable yield. Oxidation-stereoselective reduction was applied for C-3 epimerization, taking advantage of the inability of the C-2 benzoyl group to form chelates thereby favouring the hydride attack from the sterically less crowded β -side and providing the required *trans* diol. Oxidation of the free hydroxyl of **66** with PCC followed by reduction of the keto derivative with NaBH₄ indeed predominantly inverted the configuration of C-3 group to give the needed D-*altro* configured product **67** with 58% yield. This compound was converted to the 2,3-di-O-benzylated derivative **68** in two steps including Zemplén deacylation and benzylation of the liberated hydroxyls using NaH and BnBr. A dibenzoylated derivative was also formed from **67** by esterification with BzCl in dry pyridine to give the expected 2,3-di-O-benzoyl derivative **69** in good yield.



Scheme 9. Synthesis of the 6-deoxy-6-iodo-D-*altro* derivatives from D-mannoside **29**.


The C-6-OH group of the fully protected compounds (**68**, **69**) was liberated by regioselective reductive ring-opening reactions using the BH₃·THF/TMSOTf reagent combination. The primary hydroxyl in the resulting **70** and **71** was converted to a good leaving group by the treatment of Ph₃P, iodine, and imidazole to give the C-6-iodide derivatives **72** and **73** in excellent yields.

As in the case of mannosides, the dehydroiodination of altropyranosides **72** and **73** was studied using three different reagents: NaH, DBU, and AgF (Scheme 10). In the elimination reaction of the fully ether protected **72** with NaH, the expected 5,6-unsaturated compound **74** was formed in excellent yield. This exocyclic alkene was also obtained in the DBU-induced reaction with acceptable yield (58%), however, the DBU-conjugated amidinium salt **75**, formed in a concomitant nucleophilic replacement reaction, was also isolated from the reaction mixture in 41% yield. The dehydrohalogenation by AgF proceeded much more slowly than in the case of the *D-manno* configured molecule. Even after a reaction time of 48 h, the unsaturated **74** was only obtained in moderate 52% yield. No by-product was isolated from this reaction, but 19% of the starting **72** was recovered.



Scheme 10. Elimination reactions of the ether protected *D-altro* derivative (**72**).

Treatment of the 2,3-di-*O*-benzoylated derivative **73** with NaH led to, similarly to the *D-mannose* case, deacylation followed by dehydroiodination and concomitant formation of a 2,6-anhydro-altroside (**77**) by an intramolecular replacement of the 6-iodide (Scheme 11). Here, in contrast to the *manno* case, the 5,6-unsaturated **76** was isolated as the major product with 43% yield, and the 2,6-anhydrosugar by-product **77** was formed only in 22% yield.




Scheme 11. Elimination reactions of the 2,3-di-*O*-benzoyl *D-altro* derivative (**73**).

The diol **76** was efficiently converted to the required **78** by routine esterification with benzoyl chloride. In the DBU-induced reaction, formation of the expected alkene **78** was accompanied, as in the previous reactions, by a nucleophilic substitution reaction leading to the quaternary amidinium salt **79** (42%). The AgF mediated reaction yielded the expected


5,6-unsaturated **78** in a moderate yield (53%), and by-product **47**, derived from a secondary elimination of **78** to a 2,5-dienoside followed by an allylic rearrangement reaction, was also isolated. Importantly, this compound was identical to those formed from mannoside **38** under the same conditions.

After successfully synthesizing the 5,6-unsaturated **74** and **78**, C-5 epimerization was performed on both derivatives using the hydroboration/oxidation reaction described previously (Scheme 12).



Scheme 12. Hydroboration/oxidation reaction (C-5 epimerization) of the 5,6-unsaturated *D-altro* derivatives (**74**, **78**).

The expected *L-galacto* configured products were formed in the reactions in good yields (**80**, **81**) and the corresponding *D-altro* epimers were not detected in the reaction mixtures. As observed for mannoside-derived alkenes, C-5 epimerization was more efficient with ester protection than with ether protection. Following the epimerization scheme developed for *L-guloside*, the obtained *L-galacto* derivatives (**80**, **81**) were converted to the corresponding *L-gluco* epimers (**86**, **87**) in three steps (Scheme 13).



Scheme 13. C-4 epimerization of the *L-galacto* derivatives.

First, as before, in a combination of a DDQ-mediated oxidative acetal cyclization (**82**, **83**) and a regioselective reductive ring-opening reaction, the NAP group at position C-4 was moved to position C-6, thus releasing the 4-OH group (**84**, **85**). The 4,6-acetalated *L-galacto* derivative **83** was produced in crystalline form and its structure was confirmed by X-ray diffraction study (Figure 2).

In the presence of a chelating adjacent C-3-*O*-benzyl group to the resulting keto function after oxidation of **84**, the oxidation/reduction would result in reformation of the galactose isomer due to chelation to *O*-3 at the bottom face of the pyranose ring. Therefore, our attention turned to Mitsunobu isomerization as an appropriate method to convert the 3,4-*cis* diol of **84** and **85** to the required *trans* diol structure [64]. The Mitsunobu epimerization of C-4-OH was performed with *p*-nitrobenzoic acid, triphenylphosphine (Ph₃P), and diisopropyl azodicarboxylate (DIAD) reagents in dry toluene. In the case of the ether-protected derivative, the fully protected product **86** with the desired *L-gluco* configuration was obtained in good yield. However, the 2,3-*O*-benzoyl-containing compound (**85**) could only be converted to the expected *L-gluco* configured product **87** in a moderate yield of

51%. We observed that an elimination reaction also took place producing the 4-deoxy-4,5-unsaturated derivative **88** as a by-product. This compound was formed by E2 elimination of the antiperiplanar 5-H_{axial} and the oxyphosphonium ion intermediate, which is presumably facilitated by the ester groups [64,98,99].




Figure 2. ORTEP view of compound **83** at 40% probability level for better visibility with partial numbering scheme.

3. Materials and Methods

3.1. General Information

Optical rotations were measured at room temperature on a Perkin-Elmer 241 automatic polarimeter. TLC analysis was performed on Kieselgel 60 F₂₅₄ (Merck, Burlington, MA, USA) silica-gel plates with visualization by immersing in a sulphuric-acid solution (5% in EtOH) followed by heating. Column chromatography was performed on silica gel 60 (Merck 0.063–0.200 mm). Organic solutions were dried over MgSO₄ and concentrated under vacuum. ¹H and J-modulated ¹³C NMR spectroscopy (¹H: 400 and 500 MHz; ¹³C: 100.28 and 125.76 MHz) were performed on Bruker DRX-400 and Bruker Avance II 500 spectrometers at 25 °C. Chemical shifts are referenced to SiMe₄ or sodium 3-(trimethylsilyl)-1-propanesulfonate (DSS, δ = 0.00 ppm for ¹H nuclei) and to residual solvent signals (CDCl₃: δ = 77.16 ppm, CD₃OD: δ = 49.15 ppm for ¹³C nuclei). ESI-TOF MS spectra were recorded by a microTOF-Q type QqTOFMS mass spectrometer (Bruker) in the positive ion mode using MeOH as the solvent. HRMS measurements were carried out on a maXis II UHR ESI-QTOF MS instrument (Bruker, Billerica, MA, USA) in positive ionization mode. The following parameters were applied for the electrospray ion source: capillary voltage: 3.6 kV; end plate offset: 500 V; nebulizer pressure: 0.5 bar; dry gas temperature: 200 °C; and dry gas flow rate: 4.0 L/min. Constant background correction was applied for each spectrum. The background was recorded before each sample by injecting the blank sample matrix (solvent). Na-formate calibrant was injected after each sample, which enabled internal calibration during data evaluation. Mass spectra were recorded by otofControl version 4.1 (build: 3.5, Bruker) and processed by Compass DataAnalysis version 4.4 (build: 200.55.2969). Deposition Number 2163274 for compound **83** contains the supplementary crystallographic data for this paper (see Supplementary Materials). These data are provided free of charge by the joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe Access Structures service.

3.2. General Methods

3.2.1. General Method A for Iodination (25, 37, 38, 39, 72, 73)

To the solution of the corresponding 6-OH compound (**24**, **34**, **35**, **36**, **70**, and **71**) (2.662 mmol) in dry toluene (24 mL), triphenylphosphine (1.05 g, 3.993 mmol, 1.5 equiv.), imidazole (544 mg, 7.986 mmol, 3.0 equiv.), and iodine (946 mg, 3.727 mmol, 1.4 equiv.) were added. The reaction mixture was stirred at 75 °C for 30 min then cooled to room temperature. To the stirred mixture, NaHCO₃ (1.0 g) in water (14 mL) was added at room temperature. After 5 min, 10% aqueous solution of Na₂S₂O₃ (25 mL) was added and the

mixture was diluted with EtOAc (250 mL) and washed with H₂O (2 × 75 mL). The organic layer was separated, dried, filtered, and concentrated.

3.2.2. General Method B for Elimination of Iodide with DBU (26, 40, 45, 49, 74, 78)

To the solution of the appropriate 6-iodide compound (25, 37, 38, 39, 72, and 73) (0.427 mmol), dry THF (10 mL) heated to 75 °C and DBU (254 µL, 1.708 mmol, 4.0 equiv.) was added. The reaction mixture was stirred at 75 °C for 24 h. When the TLC showed complete consumption of the starting material, the reaction mixture was concentrated under reduced pressure.

3.2.3. General Method C for Hydroboration and Oxidation (28, 51, 52, 53, 80, 81)

To the solution of the appropriate 5,6-unsaturated compound (26, 40, 45, 49, 74, and 78) (0.969 mmol) in dry THF (2.5 mL), BH₃·THF complex (1M in THF, 10.1 mL, 9.690 mmol, 10.0 equiv.) was added. The reaction mixture was stirred at 0 °C for 1.5 h. After 1.5 h, 30% aqueous solution of H₂O₂ (2.5 mL) and saturated aqueous solution of NaHCO₃ (8.7 mL) were added. The reaction mixture was stirred at room temperature for 50 min (28) or 2 h (51, 52, 53, 80, 81). The mixture was diluted with EtOAc (150 mL) and washed with saturated aqueous solution of NH₄Cl (2 × 25 mL), H₂O (25 mL) and saturated aqueous solution of NaCl (25 mL) until neutral pH. The organic layer was dried and concentrated.

3.2.4. General Method D for Stereoselective Ring Opening with BH₃·THF/TMSOTf (34, 35, 36, 70, 71)

To a solution of the appropriate acetal (31, 32, 33, 68, and 69) (0.500 mmol) in dry CH₂Cl₂ (5.0 mL), BH₃·THF complex (1M in THF, 2.5 mL, 2.500 mmol, 5.0 equiv.) and TMSOTf (14 µL, 0.075 mmol, 0.15 equiv.) were added at 0 °C and the reaction mixture was stirred under argon for 1.5 h (34), 2 h (36, 70, 71), or 2.5 h (35) at room temperature. Next, Et₃N (1.0 mL) was added, followed by careful addition of MeOH until the H₂ evolution ceased. The mixture was concentrated, and the residue was coevaporated with MeOH (3 × 10 mL).

3.2.5. General Method E for Elimination of Iodide with NaH (40, 43, 48, 74, 76)

A vigorously stirred solution of the corresponding 6-iodide compound (37, 38, 39, 72, and 73) (0.703 mmol) in dry DMF (4.6 mL) was cooled to 0 °C, NaH (2.812 mmol, 4.0 equiv.) was added, and the reaction mixture was stirred at room temperature for 5 h (43), 6 h (48), or 24 h (40, 74, 76). After the complete disappearance of the starting material, MeOH (0.5 mL) was added, and the mixture was concentrated. The residue was dissolved in CH₂Cl₂ (50 mL) and washed with H₂O (2 × 10 mL). The organic layer was separated, dried, filtered and concentrated.

3.2.6. General Method F for Elimination of Iodide with AgF (40, 45, 49, 74, 78)

A solution of the appropriate 6-iodide compound (37, 38, 39, 72, and 73) (0.427 mmol) in dry pyridine (5.0 mL) under argon atmosphere AgF (270 mg, 2.135 mmol, 5.0 equiv.) was added and the mixture was stirred at room temperature for 24 h (40, 45, 49) or 48 h (74, 78) in dark. After that time, the reaction mixture was diluted with Et₂O (100 mL), and the solution was filtered through a pad of Cellite, washed with Et₂O, and concentrated.

3.2.7. General Method G for Ring Closing with DDQ (54, 55, 56, 82, 83)

To a vigorously stirred solution of the corresponding 6-OH compound (51, 52, 53, 80, and 81) (1.402 mmol) in dry CH₂Cl₂ (42 mL), DDQ (478 mg, 2.104 mmol, 1.5 equiv.) and 4 Å MS (400 mg) were added and the reaction mixture was stirred for 2 h at 0 °C. After 2 h, the mixture was diluted with CH₂Cl₂ (350 mL), filtered, washed with a saturated aqueous solution of NaHCO₃ (2 × 65 mL) and H₂O (2 × 65 mL). The organic layer was then dried, filtered and concentrated.

3.2.8. General Method H for Stereoselective Ring Opening with $\text{Me}_3\text{N}\cdot\text{BH}_3/\text{AlCl}_3$ (57, 58, 59, 84, 85)

To a solution of the appropriate 4,6-acetal (54, 55, 56, 82, and 83) (0.145 mmol) in dry THF (500 μL), 4 Å MS (111 mg) and $\text{Me}_3\text{N}\cdot\text{BH}_3$ (64 mg, 0.874 mmol, 6.0 equiv.) were added and the reaction mixture was stirred for 30 min at room temperature. After 30 min, the reaction mixture was cooled to 0 °C and AlCl_3 (117 mg, 0.874 mmol, 6.0 equiv.) was added, the cooling medium was removed, and the mixture was stirred at room temperature for 1 h. After 1 h, the reaction mixture was diluted with CH_2Cl_2 (100 mL) and washed with H_2O (2×15 mL). The organic layer was dried, filtered, and concentrated.

3.2.9. General Method I for Oxidation with PCC (60, 61, 62)

To the solution of the corresponding 4-OH compound (57, 58, and 59) (0.270 mmol) in dry CH_2Cl_2 (3.5 mL), 4 Å MS (10 p.) and PCC (233 mg, 1.080 mmol, 4.0 equiv.) were added under argon and stirred for 5 h at room temperature. After 5 h, the reaction mixture was diluted with *n*-hexane/ Et_2O = 1:1 (5.0 mL) and filtered through a pad of Celite. The filtrate was concentrated under reduced pressure.

3.2.10. General Method J for Reduction with L-Selectride (63, 64, 65)

L-Selectride (1.0 M in THF; 254 μL , 0.254 mmol, 1.5 equiv.) was added to a solution of the corresponding 4-keto compound (60, 61, and 62) (0.169 mmol) in dry THF (2.0 mL) at -78 °C under argon. The reaction mixture was stirred at -78 °C for 1 h, then the temperature was raised to -20 °C over a period of 1 h. Subsequently, the reaction was quenched with water, and the mixture was extracted with CH_2Cl_2 (3×25 mL). The combined organic extracts were washed with saturated aqueous solution of NaHCO_3 and brine, dried, filtered, and concentrated.

3.2.11. General Method K for C-4 Epimerization by Mitsunobu Reaction (86, 87)

To the solution of the appropriate 4-OH compound (84 and 85) (0.040 mmol) in toluene (440 μL) Ph_3P (0.242 mmol, 6.0 equiv.), *p*-nitrobenzoic acid (0.242 mmol, 6.0 equiv.) and diisopropyl azodicarboxylate (0.242 mmol, 6.0 equiv.) were added. The mixture was stirred at room temperature under argon atmosphere for 15 h. Subsequently, the reaction was quenched with saturated aqueous solution of NaHCO_3 , and the mixture was extracted with CH_2Cl_2 (3×25 mL). The combined organic extracts were washed with water (10 mL), dried, filtered, and concentrated.

3.2.12. Synthesis of L-Gulose and L-Allose Derivatives from D-Mannose

Phenyl 2,4-di-O-benzyl-3-O-(2'-naphthyl)methyl-1-thio- α -D-mannopyranoside (24). The acetal derivative 23 [79] (2.53 g, 4.272 mmol) was dissolved in anhydrous CH_2Cl_2 (38.5 mL) and anhydrous Et_2O (13 mL). LiAlH_4 (729 mg, 19.224 mmol, 4.5 equiv.) was added, and then a solution of AlCl_3 (2.57 g, 19.224 mmol, 4.5 equiv.) in anhydrous Et_2O (13 mL) was added. The reaction mixture was stirred at 0 °C for 1 h. The reaction mixture was diluted with EtOAc (86 mL) and H_2O (21.5 mL), the precipitated solid was filtered through a pad of Celite, and the filter cake was washed with ethyl acetate. The filtrate was washed with water (2×25 mL), dried over MgSO_4 , filtered and concentrated. The crude product was purified by silica gel chromatography (7:3 *n*-hexane/ EtOAc) to give 24 (2.01 g, 79%) as a colorless syrup. $[\alpha]_{\text{D}}^{25} +51.2$ (*c* 0.54, CHCl_3); R_f 0.38 (7:3 *n*-hexane/ EtOAc); ^1H NMR (500 MHz, CDCl_3) δ = 7.84–7.26 (22H, arom.), 5.51 (s, 1H, H-1), 4.99 (d, J = 10.9 Hz, 1H, BnCH_2a), 4.81–4.67 (m, 5H, BnCH_2b , BnCH_2 , NAPCH_2), 4.14–4.12 (m, 1H, H-5), 4.07 (t, J = 9.3 Hz, 1H, H-4), 4.02 (s, 1H, H-2), 3.96 (d, J = 8.9 Hz, 1H, H-3), 3.86–3.80 (m, 2H, H-6-a,b), 1.83 (t, J = 6.2 Hz, 1H, C-6-OH) ppm; ^{13}C NMR (100 MHz, CDCl_3) δ = 138.4, 137.9, 135.7, 134.0, 133.4, 133.1 (6C, $6 \times \text{C}_q$ arom.), 132.0–126.0 (22C, arom.), 86.1 (1C, C-1), 80.2 (1C, C-3), 76.5 (1C, C-2), 75.5 (1C, NAPCH_2), 74.9 (1C, C-4), 73.4 (1C, C-5), 72.4 (2C, $2 \times \text{BnCH}_2$), 62.3 (1C, C-6) ppm; ESI-TOF-MS: m/z calcd for $\text{C}_{37}\text{H}_{36}\text{NaO}_5\text{S} [\text{M} + \text{Na}]^+$ 615.2176; found: 615.2168.

Phenyl 2,4-di-O-benzyl-6-deoxy-6-iodo-3-O-(2'-naphthyl)methyl-1-thio- α -D-mannopyranoside (25). Compound **24** (1.94 g, 3.270 mmol) was converted to **25** according to general **Method A**. The crude product was purified by silica gel chromatography (8:2 *n*-hexane/EtOAc) to give **25** (1.52 g, 66%) as a colorless syrup. $[\alpha]_D^{25} + 50.5$ (c 0.21, CHCl₃); R_f 0.72 (7:3 *n*-hexane/EtOAc); ¹H NMR (500 MHz, CDCl₃) δ = 7.84–7.22 (22H, arom.), 5.58 (s, 1H, H-1), 5.04 (d, J = 10.9 Hz, 1H, BnCH₂a), 4.74–4.72 (m, 4H, NAPCH₂, BnCH₂), 4.64 (d, J = 12.3 Hz, 1H, BnCH₂b), 4.04 (s, 1H, H-2), 3.96–3.93 (m, 3H, H-3, H-4, H-5), 3.53 (d, J = 10.3 Hz, 1H, H-6a), 3.43 (dd, J = 5.1 Hz, J = 10.4 Hz, 1H, H-6b) ppm; ¹³C NMR (125 MHz, CDCl₃) δ = 138.4, 137.9, 135.5, 134.2, 133.4, 133.1 (6C, 6 \times C_q arom.), 131.8–126.0 (22C, arom.), 85.9 (1C, C-1), 79.9, 78.7 (2C, C-3, C-4), 76.5 (1C, C-2), 75.7 (1C, NAPCH₂), 72.2 (1C, C-5), 72.2, 72.1 (2C, 2 \times BnCH₂), 7.1 (1C, C-6) ppm; ESI-TOF-MS: m/z calcd for C₃₇H₃₅INaO₄S [M + Na]⁺ 725.1193; found: 725.1195.

Phenyl 2,4-di-O-benzyl-3-O-(2'-naphthyl)methyl-1-thio- α -D-lyxo-hex-5-enopyranoside (26) and *8-N-[phenyl 2,4-di-O-benzyl-6-deoxy-6-yl-3-O-(2'-naphthyl)methyl-1-thio- α -D-mannopyranoside]-1,8-diazabicyclo(5.4.0)undec-7-ene-iodide (27)*.

Reaction I: Compound **25** (439 mg, 0.625 mmol) was converted to **26** according to general **Method B** using DBU (372 μ L, 2.500 mmol, 4.0 equiv.) and refluxed (70 °C) for 5 h. The crude product was purified by silica gel chromatography (8:2 *n*-hexane/acetone) to give **26** (155 mg, 43%) as a colorless syrup and **27** (45 mg, 12%) as a colorless syrup.

Reaction II: To a solution of compound **25** (323 mg, 0.460 mmol) in dry toluene (4.0 mL), DBU (274 μ L, 1.839 mmol, 4.0 equiv.) was added and the mixture was stirred for 2 h at 110 °C. The reaction mixture was diluted with CH₂Cl₂ (100 mL), washed with 10% aqueous solution of Na₂S₂O₃ (20 mL), 1M aqueous solution of HCl (2 \times 20 mL), saturated aqueous solution of NaHCO₃ (20 mL), and H₂O (2 \times 20 mL) until neutral pH. The organic layer was dried over MgSO₄, filtered, and concentrated. The crude product was purified by silica gel chromatography (8:2 *n*-hexane/acetone \rightarrow 9:1 CH₂Cl₂/MeOH) to give **26** (107 mg, 40%) as a colorless syrup and **27** (73 mg, 22%) as a light yellow syrup.

Reaction III: Compound **25** (328 mg, 0.467 mmol) was converted to **26** according to general **Method B** using DBU (278 μ L, 1.868 mmol, 4.0 equiv.) and refluxed for 24 h. The crude product was purified by silica gel chromatography (8:2 *n*-hexane/acetone \rightarrow 9:1 CH₂Cl₂/MeOH) to give **26** (141 mg, 53%) as a colorless syrup and **27** (94 mg, 28%) as a light yellow syrup.

Data of **26**: $[\alpha]_D^{25} + 53.5$ (c 0.14, CHCl₃); R_f 0.43 (8:2 *n*-hexane/acetone); ¹H NMR (500 MHz, CDCl₃) δ = 7.81–7.22 (m, 22H, arom), 5.48 (d, J = 4.7 Hz, 1H, H-1), 4.86–4.60 (m, 8H, H-6a,b, 2 \times BnCH₂, NAPCH₂), 4.29 (d, J = 7.5 Hz, 1H, H-4), 4.02 (d, J = 3.3 Hz, 1H, H-2), 3.94 (dd, J = 1.6 Hz, J = 7.2 Hz, 1H, H-3) ppm; ¹³C NMR (125 MHz, CDCl₃) δ = 154.5 (1C, C-5), 138.2, 137.9, 135.8, 133.7, 133.3, 133.1 (6C, 6 \times C_q arom.), 132.0–125.9 (22C, arom.), 99.1 (1C, C-6), 86.4 (1C, C-1), 77.3 (1C, C-3), 76.3 (1C, C-4), 76.0 (1C, C-2), 73.1, 72.8 (3C, 2 \times BnCH₂, NAPCH₂) ppm; ESI-TOF-MS: m/z calcd for C₃₇H₃₄NaO₄S [M + Na]⁺ 597.2070; found: 597.2070.

Data of **27**: $[\alpha]_D^{25} + 66.7$ (c 0.24, CHCl₃); R_f 0.49 (9:1 CH₂Cl₂/MeOH); ¹H NMR (400 MHz, MeOD) δ = 7.85–7.26 (m, 22H, arom.), 5.83 (s, 1H, H-1), 5.00–4.63 (m, 6H, 2 \times BnCH₂, NAPCH₂), 4.17–4.15 (m, 1H, H-2), 4.06 (td, J = 1.7 Hz, J = 9.4 Hz, 1H, H-5), 3.97 (dd, J = 3.0 Hz, J = 9.1 Hz, 1H, H-3), 3.75 (t, J = 9.5 Hz, 1H, H-4), 3.69–3.60 (m, 2H, H-6a,b), 3.54–3.46 (m, 2H, NCH₂ DBU), 3.25–3.16 (m, 4H, 2 \times NCH₂ DBU), 2.70–2.59 (m, 2H, CH₂ DBU), 1.67–1.27 (m, 8H, 4 \times CH₂ DBU) ppm; ¹³C NMR (100 MHz, MeOD) δ = 168.5 (1C, C_q DBU), 139.5, 139.3, 136.7, 134.7, 134.5, 134.1 (6C, 6 \times C_q arom.), 132.3–127.2 (22C, arom.), 85.2 (1C, C-1), 80.9 (1C, C-3), 77.1, 76.9 (2C, C-2, C-4), 76.1, 73.8, 72.7 (3C, 2 \times BnCH₂, NAPCH₂), 72.3 (1C, C-5), 56.0, 55.7, 50.0, 49.6 (4C, C-6, 3 \times NCH₂ DBU), 29.2, 29.1, 26.8, 23.8, 20.7 (5C, 5 \times CH₂ DBU) ppm; UHR ESI-QTOF: m/z calcd for C₄₆H₅₁N₂O₄S [M]⁺ 727.3564; found: 727.3568.

Phenyl 2,4-di-O-benzyl-3-O-(2'-naphthyl)methyl-1-thio- β -L-gulopyranoside (28). Compound **26** (190 mg, 0.331 mmol) was converted to **28** according to general **Method C**. The crude product was purified by silica gel chromatography (7:3 *n*-hexane/EtOAc) to give

28 (104 mg, 53%) as a colorless syrup and **24** (24 mg, 12%) as a colorless syrup. $[\alpha]_D^{25} + 11.4$ (*c* 0.21, CHCl_3); R_f 0.33 (6:4 *n*-hexane/acetone); $^1\text{H NMR}$ (500 MHz, CDCl_3) $\delta = 7.82\text{--}6.94$ (m, 22H, arom.), 5.27 (d, $J = 9.8$ Hz, 1H, H-1), 4.84–4.14 (m, 6H, $2 \times \text{BnCH}_2$, NAPCH₂), 3.98 (d, $J = 4.5$ Hz, 1H, H-5), 3.84–3.80 (m, 1H, H-6a), 3.76 (s, 2H, H-2, H-3), 3.50 (d, $J = 8.4$ Hz, 1H, H-6b), 3.39 (s, 1H, H-4), 1.91 (s, 1H, C-6-OH) ppm; $^{13}\text{C NMR}$ (125 MHz, CDCl_3) $\delta = 138.0, 137.6, 135.6, 134.1, 133.2, 133.1$ (6C, $6 \times \text{C}_q$ arom.), 131.7–126.1 (22C, arom.), 84.2 (1C, C-1), 76.0 (1C, C-5), 75.3 (1C, C-4), 75.1 (1C, C-3), 73.6, 73.1, 72.2 (3C, $2 \times \text{BnCH}_2$, NAPCH₂), 72.7 (1C, C-2), 62.5 (1C, C-6) ppm; ESI-TOF-MS: m/z calcd for $\text{C}_{37}\text{H}_{36}\text{NaO}_5\text{S}$ $[\text{M} + \text{Na}]^+$ 615.2176; found: 615.2174.

Phenyl 3-O-benzyl-4,6-O-(2'-naphthyl)methylidene-1-thio- α -D-mannopyranoside (30). To a solution of compound **29** [91] (4.09 g, 10.00 mmol) in dry toluene (71 mL), dibutyltin oxide (3.644 g, 15.00 mmol, 1.5 equiv.) was added. The solution was refluxed (110 °C) under argon atmosphere for 4 h. Then, after cooling to room temperature, the solvent was evaporated to dryness and the crude product was dried on high vacuum for 2 h. The residue was dissolved in dry DMF (36 mL), and CsF (3.04 g, 2.001 mmol) and BnBr (1.78 mL, 15.00 mmol, 1.5 equiv.) were added. The reaction mixture was stirred at 90 °C for 24 h. The reaction mixture was filtered and evaporated to dryness. The residue was dissolved in EtOAc (250 mL) and washed with H₂O (2×25 mL). The organic layer was separated, dried over MgSO₄, filtered, and concentrated under reduced pressure. The crude product was purified by crystallization from acetone/*n*-hexane to give **30** (3.59 g, 73%) as white crystals. $[\alpha]_D^{25} + 244.2$ (*c* 0.19, CHCl_3); M.p. = 194–197 °C (acetone/*n*-hexane); R_f 0.32 (7:3 *n*-hexane/acetone); $^1\text{H NMR}$ (400 MHz, CDCl_3) $\delta = 7.98\text{--}7.20$ (m, 17H, arom.), 5.75 (s, 1H, H_{ac}), 5.59 (s, 1H, H-1), 4.88 (d, $J = 11.8$ Hz, 1H, BnCH₂a), 4.74 (d, $J = 11.8$ Hz, 1H, BnCH₂b), 4.38 (td, $J = 4.8$ Hz, $J = 9.7$ Hz, 1H, H-5), 4.26–4.21 (m, 3H), 3.98 (dd, $J = 3.2$ Hz, $J = 9.5$ Hz, 1H), 3.90 (t, $J = 10.2$ Hz, 1H), 3.02 (d, $J = 5.3$ Hz, 1H, C-2-OH) ppm; $^{13}\text{C NMR}$ (100 MHz, CDCl_3) $\delta = 137.8, 134.9, 133.7, 133.4, 133.0$ (5C, $5 \times \text{C}_q$ arom.), 131.8–123.9 (17C, arom.), 101.9 (1C, C_{ac}), 88.0 (1C, C-1), 79.2, 75.9, 71.5, 64.8 (4C, C-2, C-3, C-4, C-5), 73.3 (1C, BnCH₂), 68.7 (1C, C-6) ppm; ESI-TOF-MS: m/z calcd for $\text{C}_{30}\text{H}_{28}\text{NaO}_5\text{S}$ $[\text{M} + \text{Na}]^+$ 523.1550; found: 523.1545.

Phenyl 2-O-benzoyl-3-O-benzyl-4,6-O-(2'-naphthyl)methylidene-1-thio- α -D-mannopyranoside (31). To a stirred solution of compound **30** (3.48 g, 5.807 mmol) in dry pyridine (15 mL), BzCl (0.85 mL, 7.259 mmol, 1.25 equiv./OH) was added at 0 °C and the reaction mixture was stirred for 24 h at room temperature. After 24 h, the mixture was diluted with CH₂Cl₂ (300 mL), washed with H₂O (2×75 mL), 1M aqueous solution of H₂SO₄ (2×75 mL), H₂O (2×75 mL), saturated aqueous solution of NaHCO₃ (2×75 mL), and H₂O (2×75 mL) until neutral pH. The organic layer was dried over MgSO₄, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel chromatography (7:3 *n*-hexane/acetone) to give **31** (3.56 g, 72%) as a colorless syrup. $[\alpha]_D^{25} + 73.3$ (*c* 0.34, CHCl_3); R_f 0.52 (7:3 *n*-hexane/acetone); $^1\text{H NMR}$ (500 MHz, CDCl_3) $\delta = 8.12\text{--}7.20$ (m, 22H, arom.), 5.87 (s, 1H, H_{ac}), 5.85 (s, 1H, H-2), 5.64 (s, 1H, H-1), 4.76 (q, $J = 12.2$ Hz, 2H, BnCH₂), 4.49–4.47 (m, 1H, H-5), 4.36–4.32 (m, 2H, H-4, H-6a), 4.17 (d, $J = 9.6$ Hz, 1H, H-3), 3.97 (t, $J = 10.1$ Hz, 1H, H-6b) ppm; $^{13}\text{C NMR}$ (125 MHz, CDCl_3) $\delta = 165.8$ (1C, C_q Bz), 137.8, 134.9, 133.8, 133.2, 133.1, 129.7 (6C, $6 \times \text{C}_q$ arom.), 133.5–123.9 (22C, arom.), 102.0 (1C, C_{ac}), 87.4 (1C, C-1), 79.1 (1C, C-4), 74.4 (1C, C-3), 72.3 (1C, BnCH₂), 72.0 (1C, C-2), 68.7 (1C, C-6), 65.4 (1C, C-5) ppm; ESI-TOF-MS: m/z calcd for $\text{C}_{37}\text{H}_{32}\text{NaO}_6\text{S}$ $[\text{M} + \text{Na}]^+$ 627.1812; found: 627.1819.

Phenyl 2,3-di-O-benzyl-4,6-O-(2'-naphthyl)methylidene-1-thio- α -D-mannopyranoside (32). To a solution of compound **29** [91] (3.99 g, 9.840 mmol) in dry DMF (43 mL), NaH (60%, 984 mg, 24.60 mmol, 1.25 equiv./OH) was added in portions at 0 °C. After 30 min at that temperature, BnBr (2.8 mL, 23.61 mmol, 1.25 equiv./OH) was added and the mixture was stirred for 24 h at room temperature. Next, MeOH (5.0 mL) was added, the reaction mixture was stirred for 15 min, and the solvents were evaporated. The residue was dissolved in CH₂Cl₂ (300 mL) and washed in H₂O (3×50 mL) until neutral pH. The organic layer was dried over MgSO₄ and concentrated. The crude product was purified by silica gel

chromatography (9:1 *n*-hexane/acetone) to give **32** (3.75 g, 65%) as a colorless syrup. $[\alpha]_D^{25} + 116.5$ (c 0.36, CHCl₃); R_f 0.29 (9:1 *n*-hexane/acetone); ¹H NMR (400 MHz, CDCl₃) δ = 8.00–7.22 (m, 22H, arom.), 5.80 (s, 1H, H_{ac}), 5.53 (d, J = 1.2 Hz, 1H, H-1), 4.83 (d, J = 12.2 Hz, 1H, BnCH₂a), 4.73 (s, 2H, BnCH₂), 4.67 (d, J = 12.2 Hz, 1H, BnCH₂b), 4.41–4.33 (m, 2H, H-5, H-6a), 4.27 (dd, J = 4.4 Hz, J = 10.2 Hz, 1H, H-6b), 4.07 (dd, J = 1.3 Hz, J = 3.1 Hz, 1H, H-2), 4.00 (dd, J = 3.2 Hz, J = 9.4 Hz, 1H, H-3), 3.94 (t, J = 9.8 Hz, 1H, H-4) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 138.5, 137.9, 135.1, 133.9, 133.7, 133.1 (6C, 6 × C_q arom.), 131.8–123.9 (22C, arom.), 101.8 (1C, C_{ac}), 87.3 (1C, C-1), 79.3, 78.2, 76.4 (3C, C-2, C-3, C-4), 73.2, 73.1 (2C, 2 × BnCH₂), 68.7 (1C, C-6), 65.6 (1C, C-5) ppm; ESI-TOF-MS: m/z calcd for: C₃₇H₃₄NaO₅S [M + Na]⁺ 613.2019; found: 613.2039.

Phenyl 2,3-di-O-benzoyl-4,6-O-(2'-naphthyl)methylidene-1-thio- α -D-mannopyranoside (33). To a stirred solution of compound **29** [91] (4.10 g, 10.10 mmol) in pyridine (25 mL), BzCl (2.92 mL, 25.20 mmol, 1.25 equiv./OH) was added at 0 °C and the reaction mixture was stirred for 24 h at room temperature. After 24 h, the mixture was diluted with CH₂Cl₂ (300 mL), washed with H₂O (150 mL), 1M aqueous solution of H₂SO₄ (2 × 150 mL), H₂O (150 mL), saturated aqueous solution of NaHCO₃ (2 × 150 mL), and H₂O (150 mL) until neutral pH. The organic layer was separated, dried over MgSO₄, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel chromatography (7:3 *n*-hexane/acetone) to give **33** (4.38 g, 71%) as a colorless syrup. $[\alpha]_D^{25} - 15.7$ (c 0.22, CHCl₃); R_f 0.46 (7:3 *n*-hexane/acetone); ¹H NMR (500 MHz, CDCl₃) δ = 8.10–7.23 (m, 22H, arom.), 5.99 (dd, J = 1.3 Hz, J = 3.4 Hz, 1H, H-2), 5.86 (dd, J = 3.4 Hz, J = 10.3 Hz, 1H, H-3), 5.84 (s, 1H, H_{ac}), 5.70 (d, J = 1.1 Hz, 1H, H-1), 4.69 (td, J = 4.8 Hz, J = 9.8 Hz, 1H, H-5), 4.48 (t, J = 9.9 Hz, 1H, H-6a), 4.38 (dd, J = 4.9 Hz, J = 10.4 Hz, 1H, H-4), 4.03 (t, J = 10.3 Hz, 1H, H-6b) ppm; ¹³C NMR (125 MHz, CDCl₃) δ = 165.6, 165.4 (2C, 2 × C_q Bz), 134.5, 133.8, 133.0, 129.7, 129.6 (6C, 6 × C_q arom.), 133.8–123.9 (22C, arom.), 102.3 (1C, C_{ac}), 87.2 (1C, C-1), 77.2, 72.6, 69.4, 65.5 (4C, C-2, C-3, C-4, C-5), 68.8 (1C, C-6) ppm; ESI-TOF-MS: m/z calcd for: C₃₇H₃₀NaO₇S [M + Na]⁺ 641.1604; found: 641.1603.

Phenyl 2,3-di-O-benzyl-4-O-(2'-naphthyl)methyl-1-thio- α -D-mannopyranoside (34). Compound **32** (3.46 g, 5.850 mmol) was converted to **34** according to general **Method D**. The crude product was purified by silica gel chromatography (7:3 *n*-hexane/acetone) to give **34** (3.44 g, 99%) as a colorless syrup. $[\alpha]_D^{25} + 81.4$ (c 0.37, CHCl₃); R_f 0.39 (7:3 *n*-hexane/acetone); ¹H NMR (500 MHz, CDCl₃) δ = 7.81–7.27 (m, 22H, arom.), 5.52 (s, 1H, H-1), 5.10 (d, J = 11.1 Hz, 1H, BnCH₂a), 4.83 (d, J = 11.0 Hz, 1H, BnCH₂b), 4.69 (s, 2H, NAPCH₂), 4.65 (s, 2H, BnCH₂), 4.17–4.15 (m, 1H, H-5), 4.10 (t, J = 9.3 Hz, 1H, H-4), 4.02 (s, 1H, H-2), 3.92 (d, J = 8.9 Hz, 1H, H-3), 3.86–3.82 (m, 2H, H-6-a,b), 1.88 (s, 1H, C-6-OH) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 138.2, 137.9, 135.9, 134.0, 133.4, 133.1 (6C, 6 × C_q arom.), 132.0–126.0 (22C, arom.), 86.2 (1C, C-1), 80.2 (1C, C-3), 76.5 (1C, C-2), 75.4 (1C, NAPCH₂), 74.5 (1C, C-4), 73.4 (1C, C-5), 72.5, 72.3 (2C, 2 × BnCH₂), 62.3 (1C, C-6) ppm; ESI-TOF-MS: m/z calcd for C₃₇H₃₆NaO₅S [M + Na]⁺ 615.2176; found: 615.2196.

Phenyl 2,3-di-O-benzoyl-4-O-(2'-naphthyl)methyl-1-thio- α -D-mannopyranoside (35). Compound **33** (4.83 g, 7.788 mmol) was converted to **35** according to general **Method D**. The crude product was purified by silica gel chromatography (65:35 *n*-hexane/acetone) to give **35** (4.16 g, 95%) as a colorless syrup. $[\alpha]_D^{25} + 8.1$ (c 0.32, CHCl₃); R_f 0.46 (6:4 *n*-hexane/acetone); ¹H NMR (500 MHz, CDCl₃) δ = 8.01–7.24 (m, 22H, arom.), 5.86 (d, J = 1.3 Hz, 1H, H-2), 5.79 (dd, J = 3.2 Hz, J = 8.9 Hz, 1H, H-3), 5.65 (s, 1H, H-1), 4.89 (s, 2H, NAPCH₂), 4.44–4.41 (m, 2H, H-4, H-5), 3.96 (s, 2H, H-6a,b), 1.92 (s, 1H, H-6-OH) ppm; ¹³C NMR (125 MHz, CDCl₃) δ = 165.5, 165.4 (2C, 2 × C_q Bz), 135.1, 133.3, 133.2, 133.1, 129.6 (6C, 6 × C_q arom.), 133.6–126.1 (22C, arom.), 86.2 (1C, C-1), 75.3 (1C, NAPCH₂), 73.3, 73.0 (2C, C-4, C-5), 72.7 (1C, C-3), 72.6 (1C, C-2), 61.8 (1C, C-6) ppm; ESI-TOF-MS: m/z calcd for C₃₇H₃₂NaO₇S [M + Na]⁺ 643.1761; found: 643.1742.

Phenyl 2-O-benzoyl-3-O-benzyl-4-O-(2'-naphthyl)methyl-1-thio- α -D-mannopyranoside (36). Compound **31** (3.56 g, 5.899 mmol) was converted to **36** according to general **Method D**. The crude product was purified by silica gel chromatography (7:3 *n*-hexane/acetone) to give **36** (2.82 g, 79%) as a colorless syrup. $[\alpha]_D^{25} + 68.6$ (c 0.29, CHCl₃); R_f 0.42 (7:3

n-hexane/acetone); ^1H NMR (500 MHz, CDCl_3) δ = 8.06–7.24 (m, 22H, arom.), 5.86 (s, 1H, H-2), 5.59 (d, J = 0.9 Hz, 1H, H-1), 5.11–4.62 (m, 4H, NAPCH₂, BnCH₂), 4.29–4.27 (m, 1H, H-5), 4.12–4.11 (m, 2H, H-3, H-4), 3.90–3.87 (m, 2H, H-6a,b), 1.82 (t, J = 6.6 Hz, 1H, C-6-OH) ppm; ^{13}C NMR (125 MHz, CDCl_3) δ = 165.7 (1C, C_q Bz), 137.8, 135.7, 133.4, 133.2, 129.8 (6C, 6 × C_q arom.), 133.5–126.1 (22C, arom.), 86.6 (1C, C-1), 78.6 (1C, C-3), 75.5 (1C, NAPCH₂), 74.2 (1C, C-4), 73.2 (1C, C-5), 71.9 (1C, BnCH₂), 70.9 (1C, C-2), 62.2 (1C, C-6) ppm; ESI-TOF-MS: m/z calcd for C₃₇H₃₄NaO₆S [M + Na]⁺ 629.1968; found: 629.2028.

Phenyl 2,3-di-O-benzyl-6-deoxy-6-iodo-4-O-(2'-naphthyl)methyl-1-thio- α -D-mannopyranoside (37). Compound **34** (3.38 g, 5.702 mmol) was converted to **37** according to general **Method A**. The crude product was purified by silica gel chromatography (8:2 *n*-hexane/acetone) to give **37** (3.12 g, 78%) as a colorless syrup. $[\alpha]_{\text{D}}^{25}$ +57.3 (*c* 0.63, CHCl_3); R_f 0.42 (8:2 *n*-hexane/acetone); ^1H NMR (500 MHz, CDCl_3) δ = 7.82–7.22 (m, 22H, arom.), 5.59 (s, 1H, H-1), 5.15 (d, J = 11.1 Hz, 1H, BnCH₂a), 4.88 (d, J = 11.1 Hz, 1H, BnCH₂b), 4.73 (d, J = 12.3 Hz, 1H, BnCH₂a), 4.65 (d, J = 12.2 Hz, 1H, BnCH₂b), 4.61 (s, 2H, NAPCH₂), 4.03 (s, 1H, H-2), 3.97–3.94 (m, 2H, H-4, H-5), 3.91–3.90 (m, 1H, H-3), 3.54 (d, J = 10.3 Hz, 1H, H-6a), 3.44 (dd, J = 5.4 Hz, J = 10.5 Hz, 1H, H-6b) ppm; ^{13}C NMR (125 MHz, CDCl_3) δ = 138.1, 137.9, 135.8, 134.3, 133.4, 133.2 (6C, 6 × C_q arom.), 131.7–126.1 (22C, arom.), 86.0 (1C, C-1), 79.9 (1C, C-3), 78.8 (1C, C-4), 76.4 (1C, C-2), 75.7 (1C, NAPCH₂), 72.2 (1C, C-5), 72.1, 72.1 (2C, 2 × BnCH₂), 7.1 (1C, C-6) ppm; ESI-TOF-MS: m/z calcd for C₃₇H₃₅INaO₄S [M + Na]⁺ 725.1193; found: 725.1183.

Phenyl 2,3-di-O-benzoyl-6-deoxy-6-iodo-4-O-(2'-naphthyl)methyl-1-thio- α -D-mannopyranoside (38). Compound **35** (4.08 g, 5.588 mmol) was converted to **38** according to general **Method A**. The crude product was purified by silica gel chromatography (7:3 *n*-hexane/acetone) to give **38** (3.77 g, 79%) as a colorless syrup. $[\alpha]_{\text{D}}^{25}$ + 24.1 (*c* 0.22, CHCl_3); R_f 0.53 (7:3 *n*-hexane/acetone); ^1H NMR (400 MHz, CDCl_3) δ = 8.13–7.23 (m, 22H, arom.), 5.92 (s, 1H), 5.80 (dd, J = 2.6 Hz, J = 9.5 Hz, 1H), 5.68 (s, 1H), 4.95 (s, 2H, NAPCH₂), 4.32 (d, J = 9.4 Hz, 1H), 4.14–4.09 (m, 1H), 3.69 (dd, J = 3.8 Hz, J = 10.9 Hz, 1H, H-6a), 3.59–3.57 (m, 1H, H-6b) ppm; ^{13}C NMR (100 MHz, CDCl_3) δ = 165.4, 165.3 (2C, 2 × C_q Bz), 134.9, 133.2, 133.1, 133.0, 129.5, 129.4 (6C, 6 × C_q arom.), 133.6–125.9 (22C, arom.), 86.1 (1C, C-1), 75.7 (1C, NAPCH₂), 77.7, 72.5, 72.3, 70.9 (4C, C-2, C-3, C-4, C-5), 8.6 (1C, C-6) ppm; ESI-TOF-MS: m/z calcd for C₃₇H₃₁INaO₆S [M + Na]⁺ 753.0778; found: 753.0758.

Phenyl 2-O-benzoyl-3-O-benzyl-6-deoxy-6-iodo-4-O-(2'-naphthyl)methyl-1-thio- α -D-mannopyranoside (39). Compound **36** (2.77 g, 3.868 mmol) was converted to **39** according to general **Method A**. The crude product was purified by silica gel chromatography (8:2 *n*-hexane/acetone) to give **39** (3.23 g, 99%) as a colorless syrup. $[\alpha]_{\text{D}}^{25}$ + 0.6 (*c* 0.14, CHCl_3); R_f 0.43 (8:2 *n*-hexane/acetone); ^1H NMR (500 MHz, CDCl_3) δ = 8.16–7.24 (m, 22H, arom.), 5.90 (s, 1H, H-2), 5.62 (s, 1H, H-1), 5.15–4.60 (m, 4H, NAPCH₂, BnCH₂), 4.11 (d, J = 8.9 Hz, 1H, H-3), 4.02 (t, J = 9.1 Hz, 1H, H-4), 3.95 (d, J = 8.0 Hz, 1H, H-5), 3.61 (dd, J = 4.2 Hz, J = 10.8 Hz, 1H, H-6a), 3.54 (dd, J = 2.1 Hz, J = 10.7 Hz, 1H, H-6b) ppm; ^{13}C NMR (125 MHz, CDCl_3) δ = 165.7 (1C, C_q Bz), 137.6, 135.6, 133.5, 133.2, 129.8 (6C, 6 × C_q arom.), 133.5–126.1 (22C, arom.), 86.5 (1C, C-1), 78.4 (1C, C-4), 78.3 (1C, C-3), 75.8 (1C, NAPCH₂), 71.8 (1C, BnCH₂), 71.1 (1C, C-5), 70.6 (1C, C-2), 8.5 (1C, C-6) ppm; ESI-TOF-MS: m/z calcd for C₃₇H₃₃INaO₅S [M + Na]⁺ 739.0985; found: 739.0992.

Phenyl 2,3-di-O-benzyl-4-O-(2'-naphthyl)methyl-1-thio- α -D-lyxo-hex-5-enopyranoside (40). Compound **37** (300 mg, 0.427 mmol) was converted to **40** according to general **Method E**. The crude product was purified by silica gel chromatography (8:2 *n*-hexane/acetone) to give **40** (224 mg, 91%) as a colorless syrup. $[\alpha]_{\text{D}}^{25}$ + 62.6 (*c* 0.19, CHCl_3); R_f 0.38 (8:2 *n*-hexane/acetone); ^1H NMR (400 MHz, CDCl_3) δ = 7.79–7.18 (m, 22H, arom.), 5.51 (d, J = 4.7 Hz, 1H, H-1), 4.86–4.57 (m, 8H, H-6a,b, 2 × BnCH₂, NAPCH₂), 4.32 (d, J = 7.6 Hz, 1H, H-4), 4.04 (t, J = 3.5 Hz, 1H, H-2), 3.92 (dd, J = 2.1 Hz, J = 7.6 Hz, 1H, H-3) ppm; ^{13}C NMR (100 MHz, CDCl_3) δ = 154.4 (1C, C-5), 138.2, 137.8, 135.6, 133.7, 133.3, 133.0 (6C, 6 × C_q arom.), 131.8–125.8 (22C, arom.), 99.1 (1C, C-6), 86.3 (1C, C-1), 77.3 (1C, C-3), 76.1 (1C, C-4), 75.8 (1C, C-2), 72.8, 72.7, 72.6 (3C, 2 × BnCH₂, NAPCH₂) ppm; ESI-TOF-MS: m/z calcd for C₃₇H₃₄NaO₄S [M + Na]⁺ 597.2070; found: 597.2058.

Phenyl 2,3-di-O-benzyl-4-O-(2'-naphthyl)methyl-1-thio- α -D-lyxo-hex-5-enopyranoside (**40**) and 8-N-[phenyl 2,3-di-O-benzyl-6-deoxy-6-yl-4-O-(2'-naphthyl)methyl-1-thio- α -D-mannopyranoside]-1,8-diazabicyclo(5.4.0)undec-7-ene-iodide (**41**). Compound **37** (300 mg, 0.427 mmol) was converted to **40** according to general **Method B**. The crude product was purified by silica gel chromatography (7:3 CH₂Cl₂/n-hexane \rightarrow 9:1 CH₂Cl₂/MeOH) to give **40** (117 mg, 48%) as a colorless syrup and **41** (175 mg, 38%) as a light yellow syrup.

Data of **41**: $[\alpha]_D^{25} + 67.7$ (c 0.30, CHCl₃); R_f 0.49 (9:1 CH₂Cl₂/MeOH); ¹H NMR (500 MHz, CDCl₃) $\delta = 7.86$ – 7.27 (m, 22H, arom.), 5.60 (s, 1H, H-1), 5.11–4.61 (m, 6H, 2 \times BnCH₂, NAPCH₂), 4.07 (t, $J = 9.3$ Hz, 1H, H-5), 3.97 (s, 1H, H-2), 3.92–3.87 (m, 2H, H-3, H-6a), 3.77 (t, $J = 9.3$ Hz, 1H, H-4), 3.63–3.53 (m, 3H, H-6b, NCH₂ DBU), 3.46–3.40 (m, 4H, 2 \times NCH₂ DBU), 2.77–2.63 (m, 2H, CH₂ DBU), 1.77–1.43 (m, 8H, 4 \times CH₂ DBU) ppm; ¹³C NMR (125 MHz, CDCl₃) $\delta = 167.1$ (1C, C_q DBU), 137.5, 134.9, 133.2, 133.0, 132.7 (6C, 6 \times C_q arom.), 130.8–126.1 (22C, arom.), 84.5 (1C, C-1), 79.8 (1C, C-3), 75.6 (2C, C-2, C-4), 75.4, 72.7, 72.1 (3C, 2 \times BnCH₂, NAPCH₂), 55.7 (1C, NCH₂ DBU), 55.0 (1C, C-6), 49.4, 48.2 (2C, 2 \times NCH₂ DBU), 28.8, 28.2, 25.7, 22.5, 19.7 (5C, 5 \times CH₂ DBU) ppm; UHR ESI-QTOF: m/z calcd for C₄₆H₅₁N₂O₄S [M]⁺ 727.3564; found: 727.3562.

Phenyl 2,3-di-O-benzyl-4-O-(2'-naphthyl)methyl-1-thio- α -D-lyxo-hex-5-enopyranoside (**40**) and Phenyl 2,3-di-O-benzyl-6-deoxy-6-fluoro-4-O-(2'-naphthyl)methyl-1-thio- α -D-mannopyranoside (**42**). Compound **37** (300 mg, 0.427 mmol) was converted to **40** according to general **Method F**. The crude product was purified by silica gel chromatography (7:3 CH₂Cl₂/n-hexane) to give **40** (210 mg, 86%) as a colorless syrup and **42** (14 mg, 6%) as a colorless syrup.

Data of **42**: $[\alpha]_D^{25} + 60.6$ (c 1.44, CHCl₃); R_f 0.33 (7:3 CH₂Cl₂/n-hexane); ¹H NMR (500 MHz, CDCl₃) $\delta = 7.84$ – 7.25 (m, 22H, arom.), 5.59 (d, $J = 1.3$ Hz, 1H, H-1), 5.14–4.54 (m, 8H, H-6a,b, 2 \times BnCH₂, NAPCH₂), 4.26 (ddd, $J = 2.7$ Hz, $J = 10.0$ Hz, $J = 27.4$ Hz, 1H, H-5), 4.12 (t, $J = 9.6$ Hz, 1H, H-4), 4.03 (dd, $J = 1.8$ Hz, $J = 2.9$ Hz, 1H, H-2), 3.91 (dd, $J = 3.0$ Hz, $J = 9.3$ Hz, 1H, H-3) ppm; ¹³C NMR (125 MHz, CDCl₃) $\delta = 138.1$, 137.8, 135.8, 134.3, 133.4, 133.1 (6C, 6 \times C_q arom.), 131.4–126.1 (22C, arom.), 86.0 (1C, C-1), 82.3 (1C, $J_{C,F} = 172.9$ Hz, H-6), 80.2, 76.2 (2C, C-2, C-3), 75.2 (1C, NAPCH₂), 74.9 (1C, $J_{C,F} = 6.6$ Hz, C-5), 72.4 (1C, C-4), 72.2 (2C, 2 \times BnCH₂) ppm; ESI-TOF-MS: m/z calcd for C₃₇H₃₅FN₂O₄S [M + Na]⁺ 617.2132; found: 617.2123.

Phenyl 4-O-(2'-naphthyl)methyl-1-thio- α -D-lyxo-hex-5-enopyranoside (**43**) and Phenyl 3,6-anhydro-4-O-(2'-naphthyl)methyl-1-thio- α -D-mannopyranoside (**44**) Compound **38** (300 mg, 0.411 mmol) was converted to **43** according to general **Method E**. The crude product was purified by silica gel chromatography (1:1 n-hexane/EtOAc) to give **43** (21 mg, 17%) as a colorless syrup and **44** (95 mg, 59%) as a colorless syrup.

Data of **43**: $[\alpha]_D^{25} + 70.4$ (c 0.28, CHCl₃); R_f 0.42 (1:1 n-hexane/EtOAc); ¹H NMR (500 MHz, CDCl₃) $\delta = 7.84$ – 7.26 (m, 12H, arom.), 5.29 (d, $J = 6.2$ Hz, 1H, H-1), 4.95 (s, 1H, H-6a), 4.89 (d, $J = 11.9$ Hz, 1H, NAPCH₂a), 4.79 (s, 1H, H-6b), 4.59 (d, $J = 11.9$ Hz, 1H, NAPCH₂b), 4.15–4.13 (m, 2H, H-2, H-3), 4.10 (d, $J = 5.6$ Hz, 1H, H-4), 2.53, 2.49 (2 \times s, 2H, H-2-OH, H-3-OH) ppm; ¹³C NMR (125 MHz, CDCl₃) $\delta = 153.8$ (1C, C-5), 135.2, 133.4, 133.2, 132.5 (4C, 4 \times C_q arom.), 132.3–125.8 (12C, arom.), 101.1 (1C, C-6), 87.6 (1C, C-1), 76.9 (1C, C-4), 71.5 (1C, NAPCH₂), 70.3 (1C, C-3), 68.5 (1C, C-2) ppm; ESI-TOF-MS: m/z calcd for C₂₃H₂₂NaO₄S [M + Na]⁺ 417.1131; found: 417.1136.

Data of **44**: $[\alpha]_D^{25} + 40.7$ (c 0.28, CHCl₃); R_f 0.28 (1:1 n-hexane/EtOAc); ¹H NMR (500 MHz, CDCl₃) $\delta = 7.83$ – 7.09 (m, 12H, arom.), 4.93 (d, $J = 8.7$ Hz, 1H, H-1), 4.78 (d, $J = 11.9$ Hz, 1H, NAPCH₂a), 4.61 (d, $J = 11.9$ Hz, 1H, NAPCH₂b), 4.47 (t, $J = 2.8$ Hz, 1H, H-5), 4.32 (dd, $J = 0.8$ Hz, $J = 6.0$ Hz, 1H, H-3), 4.12 (d, $J = 10.9$ Hz, 1H, H-6a), 3.99 (dd, $J = 2.7$ Hz, $J = 6.0$ Hz, 1H, H-4), 3.93 (dd, $J = 2.7$ Hz, $J = 10.8$ Hz, 2H, H-2, H-6b), 3.91 (t, $J = 8.0$ Hz, H-2), 2.46 (s, 1H, H-2-OH) ppm; ¹³C NMR (125 MHz, CDCl₃) $\delta = 134.7$, 133.2, 133.1, 132.7 (4C, 4 \times C_q arom.), 132.5–125.7 (12C, arom.), 85.6 (1C, C-1), 77.4 (1C, C-4), 76.9 (1C, C-3), 74.2 (1C, C-5), 71.9 (1C, NAPCH₂), 69.5 (1C, C-6), 67.6 (1C, C-2) ppm; ESI-TOF-MS: m/z calcd for C₂₃H₂₂NaO₄S [M + Na]⁺ 417.1131; found: 417.1129.

Phenyl 2,3-di-O-benzoyl-4-O-(2'-naphthyl)methyl-1-thio- α -D-lyxo-hex-5-enopyranoside (**45**) and 8-N-[phenyl 2,3-di-O-benzoyl-6-deoxy-6-yl-4-O-(2'-naphthyl)methyl-1-thio- α -D-mannopyranoside]-

1,8-diazabicyclo(5.4.0)undec-7-ene-iodide (**46**). Compound **38** (2.3 g, 3.150 mmol) was converted to **45** according to general **Method B**. The crude product was purified by silica gel chromatography (7:3 CH₂Cl₂/n-hexane → 95:5 CH₂Cl₂/MeOH) to give **45** (1.25 g, 66%) as a colorless syrup and **46** (773 mg, 31%) as a light yellow syrup.

Data of **45**: [α]_D²⁵ − 13.7 (c 0.27, CHCl₃); R_f 0.28 (7:3 CH₂Cl₂/n-hexane); ¹H NMR (400 MHz, CDCl₃) δ = 7.89–7.25 (m, 22H, arom.), 5.84–5.82 (m, 1H, H-2), 5.78 (dd, *J* = 3.2 Hz, *J* = 8.1 Hz, 1H, H-3), 5.63 (d, *J* = 4.6 Hz, 1H, H-1), 5.03 (s, 1H, H-6a), 5.00 (s, 1H, H-6b), 4.96 (d, *J* = 12.0 Hz, 1H, NAPCH₂a), 4.75 (d, *J* = 12.0 Hz, 1H, NAPCH₂b), 4.50 (d, *J* = 8.1 Hz, 1H, H-4) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 165.2 (2C, 2 × C_q Bz), 153.4 (1C, C-5) 134.9, 133.3, 133.2, 132.5, 129.5, 129.4 (6C, 6 × C_q arom.), 133.5–126.1 (22C, arom.), 100.9 (1C, C-6), 86.1 (1C, C-1) 74.0 (1C, C-4), 72.6 (1C, NAPCH₂), 70.6 (2C, C-2, C-3) ppm; ESI-TOF-MS: *m/z* calcd for C₃₇H₃₀NaO₆S [M + Na]⁺ 625.1655; found: 625.1665.

Data of **46**: [α]_D²⁵ + 27.4 (c 0.19, CHCl₃); R_f 0.31 (95:5 CH₂Cl₂/MeOH); ¹H NMR (500 MHz) δ = 8.05–7.26 (m, 22H, arom.), 5.86 (dd, *J* = 1.6 Hz, *J* = 3.1 Hz, 1H, H-2), 5.81 (d, *J* = 1.1 Hz, 1H, H-1), 5.78 (dd, *J* = 3.2 Hz, *J* = 9.4 Hz, 1H, H-3), 4.90 (d, *J* = 3.2 Hz, 2H, NAPCH₂), 4.42 (t, *J* = 9.3 Hz, 1H, H-5), 4.23 (d, *J* = 15.0 Hz, 1H, H-6a), 4.12 (t, *J* = 9.6 Hz, 1H, H-4), 3.97 (dd, *J* = 9.7 Hz, *J* = 15.8 Hz, 1H, H-6b), 3.68–3.41 (m, 6H, 3 × NCH₂ DBU), 2.80–2.79 (m, 2H, CH₂ DBU), 1.94–1.56 (m, 8H, 4 × CH₂ DBU) ppm; ¹³C NMR (125 MHz, CDCl₃) δ = 167.6 (1C, C_q DBU), 165.4, 165.3 (2C, 2 × C_q Bz), 134.2, 133.1, 132.3, 129.0, 128.9 (6C, 6 × C_q arom.), 133.9–126.1 (22C, arom.), 84.6 (1C, C-1), 75.9 (1C, NAPCH₂), 75.0 (1C, C-4), 72.5 (1C, C-3), 72.1 (1C, C-5), 71.6 (1C, C-2), 55.8 (1C, NCH₂ DBU), 55.6 (1C, C-6), 49.5, 48.5 (2C, 2 × NCH₂ DBU), 29.3, 28.5, 25.8, 22.7, 19.9 (5C, 5 × CH₂ DBU) ppm; UHR ESI-QTOF: *m/z* calcd for C₄₆H₄₇N₂O₆S [M]⁺ 755.3149; found: 755.3147.

Phenyl 2,3-di-O-benzoyl-4-O-(2'-naphthyl)methyl-1-thio- α -D-lyxo-hex-5-enopyranoside (**45**) and 1,5-anhydro-2-O-benzoyl-3,6-dideoxy-4-O-(2'-naphthyl)methyl-3-S-phenyl-3-thio- α -D-erythro-hex-1,5-dienitol (**47**). Compound **38** (300 mg, 0.411 mmol) was converted to **45** according to general **Method F**. The crude product was purified by silica gel chromatography (7:3 CH₂Cl₂/n-hexane) to give **47** (24 mg, 9%) as a colorless syrup and **45** (154 mg, 55%) as a colorless syrup.

Data of **47**: [α]_D²⁵ − 18.8 (c 0.25, CHCl₃); R_f 0.60 (7:3 CH₂Cl₂/n-hexane); ¹H NMR (400 MHz, CDCl₃) δ = 7.94–7.27 (m, 17H, arom.), 6.54 (s, 1H, H-1), 5.19 (d, *J* = 6.3 Hz, 1H, H-4), 5.08 (s, 2H, NAPCH₂), 5.00 (s, 1H, H-6a), 4.69 (s, 1H, H-6b), 4.09 (dd, *J* = 1.0 Hz, *J* = 6.3 Hz, 1H, H-3) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 164.9 (1C, C_q Bz), 148.5 (1C, C-5), 147.0 (1C, C-2), 133.8, 133.4, 133.2, 133.0, 129.5 (5C, 5 × C_q arom.), 133.6–125.1 (17C, arom.), 94.1 (1C, C-6), 93.6 (1C, C-4), 92.8 (1C, C-1), 69.7 (1C, NAPCH₂), 46.4 (1C, C-3) ppm; ESI-TOF-MS: *m/z* calcd for C₃₀H₂₄NaO₄S [M + Na]⁺ 503.1288; found: 503.1281.

Phenyl 2,6-anhydro-3-O-benzyl-4-O-(2'-naphthyl)methyl-1-thio- α -D-mannopyranoside (**48**). Compound **39** (310 mg, 0.433 mmol) was converted to **48** according to general **Method E**. The crude product was purified by silica gel chromatography (7:3 n-hexane/EtOAc) to give **48** (209 mg, 99%) as a colorless syrup. [α]_D²⁵ + 64.7 (c 0.15, CHCl₃); R_f 0.37 (7:3 n-hexane/EtOAc); ¹H NMR (500 MHz, CDCl₃) δ = 8.09–7.20 (m, 17H, arom.), 5.68 (s, 1H, H-1), 4.81–4.52 (m, 4H, NAPCH₂, BnCH₂), 4.20–4.12 (m, 4H, H-2, H-3, H-5, H-6a), 3.813 (d, *J* = 9.8 Hz, 1H, H-6b), 3.73 (s, 1H, H-4) ppm; ¹³C NMR (125 MHz, CDCl₃) δ = 137.6, 135.3, 134.3, 133.3, 133.1 (5C, 5 × C_q arom.), 133.7–126.0 (17C, arom.), 86.9 (1C, C-1), 80.6 (1C, C-4), 78.9 (1C, C-3), 71.0, 70.6 (2C, NAPCH₂, BnCH₂), 69.9 (1C, C-2), 69.7 (1C, C-5), 66.8 (1C, C-6) ppm; ESI-TOF-MS: *m/z* calcd for C₃₀H₂₈NaO₄S [M + Na]⁺ 507.1601; found: 507.1626.

Phenyl 2-O-benzoyl-3-O-benzyl-4-O-(2'-naphthyl)methyl-1-thio- α -D-lyxo-hex-5-enopyranoside (**49**) and 8-N-[phenyl 2-O-benzoyl-3-O-benzyl-6-deoxy-6-yl-4-O-(2'-naphthyl)methyl-1-thio- α -D-mannopyranoside]-1,8-diazabicyclo(5.4.0)undec-7-ene-iodide (**50**).

Reaction I: Compound **39** (336 mg, 0.469 mmol) was converted to **49** according to general **Method B**. The crude product was purified by silica gel chromatography (7:3 CH₂Cl₂/n-hexane → 95:5 CH₂Cl₂/MeOH) to give **49** (149 mg, 54%) as a colorless syrup and **50** (118 mg, 29%) as a light yellow syrup.

Reaction II: Compound **39** (1.388 g, 1.938 mmol) was converted to **49** according to general **Method F**. The crude product was purified by silica gel chromatography (7:3 *n*-hexane/EtOAc) to give **49** (991 mg, 87%) as a colorless syrup.

Data of **49**: $[\alpha]_D^{25} + 40.9$ (*c* 0.35, CHCl₃); *R*_f 0.60 (7:3 CH₂Cl₂/*n*-hexane); ¹H NMR (400 MHz, CDCl₃) δ = 8.03–7.19 (m, 22H, arom.), 5.80 (d, *J* = 3.5 Hz, 1H, H-2), 5.62 (d, *J* = 4.1 Hz, H-1), 5.00 (s, 1H, H-6a), 4.94–4.62 (m, 5H, H-6b, NAPCH₂, BnCH₂), 4.35 (d, *J* = 8.1 Hz, 1H, H-4), 4.12 (dd, *J* = 2.9 Hz, *J* = 8.1 Hz, 1H, H-3) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 165.5 (1C, C_q Bz), 154.2 (1C, C-5), 137.7, 135.4, 133.4, 133.1, 133.0, 129.7 (6C, 6 × C_q arom.), 133.4–126.0 (22C, arom.), 99.8 (1C, C-6), 86.3 (1C, C-1), 76.8 (1C, C-3), 75.5 (1C, C-4), 73.2, 72.5 (2C, NAPCH₂, BnCH₂), 70.6 (1C, C-2) ppm; ESI-TOF-MS: *m/z* calcd for C₃₇H₃₂NaO₅S [M + Na]⁺ 611.1863; found: 611.1897.

Data of **50**: $[\alpha]_D^{25} + 67.3$ (*c* 0.26, CHCl₃); *R*_f 0.63 (9:1 CH₂Cl₂/MeOH); ¹H NMR (400 MHz) δ = 8.08–7.25 (m, 22H, arom.), 5.82 (dd, *J* = 1.5 Hz, *J* = 2.7 Hz, 1H, H-2), 5.73 (s, 1H, H-1), 5.10–4.59 (m, 4H, NAPCH₂, BnCH₂), 4.23 (t, *J* = 9.4 Hz, 1H, H-5), 4.10 (dd, *J* = 3.1 Hz, *J* = 9.0 Hz, 1H, H-3), 4.04 (d, *J* = 15.0 Hz, 1H, H-6a), 3.79 (t, *J* = 9.4 Hz, 1H, H-4), 3.72 (dd, *J* = 9.7 Hz, *J* = 15.0 Hz, 1H, H-6b), 3.65–3.38 (m, 6H, 3 × NCH₂ DBU), 2.79–2.65 (m, 2H, CH₂ DBU), 1.84–1.47 (m, 8H, 4 × CH₂ DBU) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 167.1 (1C, C_q DBU), 165.4 (1C, C_q Bz), 137.0, 134.6, 133.1, 132.9, 132.1, 129.1 (6C, 6 × C_q arom.), 133.6–126.1 (22C, arom.), 84.7 (1C, C-1), 78.2 (1C, C-3), 75.4 (1C, NAPCH₂), 75.1 (1C, C-4), 71.7 (1C, C-5), 71.6 (1C, BnCH₂), 69.6 (1C, C-2), 55.6 (1C, NCH₂ DBU), 55.3 (1C, C-6), 49.3, 48.2 (2C, 2 × NCH₂ DBU), 29.0, 28.2, 25.6, 22.4, 19.7 (5C, 5 × CH₂ DBU) ppm; UHR ESI-QTOF: *m/z* calcd for C₄₆H₄₉N₂O₅S [M]⁺ 741.3357; found: 741.3357.

Phenyl 2,3-di-O-benzyl-4-O-(2'-naphthyl)methyl-1-thio-β-L-gulopyranoside (51). Compound **40** (574 mg, 1.000 mmol) was converted to **51** according to general **Method C**. The crude product was purified by silica gel chromatography (65:35 *n*-hexane/EtOAc) to give **34** (70 mg, 12%) as a colorless syrup and **51** (385 mg, 65%) as a colorless syrup.

Data of **51**: $[\alpha]_D^{25} + 3.1$ (*c* 0.35, CHCl₃); *R*_f 0.40 (65:35 *n*-hexane/EtOAc); ¹H NMR (400 MHz, CDCl₃) δ = 7.85–7.17 (m, 22H, arom.), 5.24 (d, *J* = 9.6 Hz, 1H, H-1), 4.68–4.33 (m, 6H, 2 × BnCH₂, NAPCH₂), 3.98–3.95 (m, 1H, H-5), 3.89–3.86 (m, 1H, H-6a), 3.80–3.76 (m, 2H, H-2, H-3), 3.53 (td, *J* = 4.2 Hz, *J* = 11.5 Hz, 1H, H-6b), 3.45 (dd, *J* = 1.2 Hz, *J* = 3.5 Hz, 1H, H-4), 1.78 (d, *J* = 8.5 Hz, 1H, H-6-OH) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 138.0, 137.8, 135.1, 134.1, 133.0 (6C, 6 × C_q arom.), 131.5–125.8 (22C, arom.), 84.1 (1C, C-1), 76.0 (1C, C-5), 75.2 (1C, C-4), 74.8 (1C, C-2), 73.2, 72.8, 72.4 (3C, 2 × BnCH₂, NAPCH₂), 72.6 (1C, C-3), 62.3 (1C, C-6) ppm; ESI-TOF-MS: *m/z* calcd for C₃₇H₃₆NaO₅S [M + Na]⁺ 615.2176; found: 615.2183.

Phenyl 2,3-di-O-benzoyl-4-O-(2'-naphthyl)methyl-1-thio-β-L-gulopyranoside (52). Compound **45** (1.15 g, 1.909 mmol) was converted to **52** according to general **Method C**. The crude product was purified by silica gel chromatography (65:35 *n*-hexane/EtOAc) to give **35** (100 mg, 8%) as a colorless syrup and **52** (870 mg, 74%) as a colorless syrup.

Data of **52**: $[\alpha]_D^{25} + 108.0$ (*c* 0.10, CHCl₃); *R*_f 0.32 (65:35 *n*-hexane/EtOAc); ¹H NMR (500 MHz, CDCl₃) δ = 8.01–7.26 (m, 22H, arom.), 6.02 (s, 1H, H-3), 5.57 (dd, *J* = 2.8 Hz, *J* = 10.3 Hz, 1H, H-2), 5.39 (d, *J* = 10.3 Hz, 1H, H-1), 5.07 (d, *J* = 11.9 Hz, 1H, NAPCH₂a), 4.74 (d, *J* = 11.9 Hz, 1H, NAPCH₂b), 4.10–4.08 (m, 1H, H-5), 3.99–3.96 (m, 1H, H-6a), 3.79 (d, *J* = 1.5 Hz, 1H, H-4), 3.60–3.55 (m, 1H, H-6b), 1.79 (d, *J* = 6.1 Hz, 1H, C-6-OH) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 165.3, 165.1 (2C, 2 × C_q Bz), 134.5, 133.2, 132.3, 129.6, 129.3 (6C, 6 × C_q arom.), 133.7–126.0 (22C, arom.), 83.2 (1C, C-1), 77.1 (1C, C-5), 73.5 (1C, C-4), 72.4 (1C, NAPCH₂), 67.8 (1C, C-2), 67.7 (1C, C-3), 62.3 (1C, C-6) ppm; ESI-TOF-MS: *m/z* calcd for C₃₇H₃₂NaO₇S, [M + Na]⁺ 643.1761; found: 643.1743.

Phenyl 2-O-benzoyl-3-O-benzyl-4-O-(2'-naphthyl)methyl-1-thio-β-L-gulopyranoside (53). Compound **49** (325 mg, 0.553 mmol) was converted to **53** according to general **Method C**. The crude product was purified by silica gel chromatography (65:35 *n*-hexane/EtOAc) to give **36** (20 mg, 6%) as a colorless syrup and **53** (285 mg, 84%) as a colorless syrup.

Data of **53**: $[\alpha]_D^{25} + 35.8$ (*c* 0.19, CHCl₃); *R*_f 0.41 (65:35 *n*-hexane/EtOAc); ¹H NMR (500 MHz, CDCl₃) δ = 8.09–7.10 (m, 22H, arom.), 5.42–5.36 (m, 2H, H-1, H-2), 4.80–4.43 (m,

4H, NAPCH₂, BnCH₂), 4.27–4.24 (m, 1H, H-3), 4.12–4.09 (m, 1H, H-5), 3.94 (dd, *J* = 7.6 Hz, *J* = 11.2 Hz, 1H, H-6a), 3.59 (d, *J* = 9.1 Hz, 1H, H-6b), 3.55 (s, 1H, H-4), 1.96 (s, 1H, C-6-OH) ppm; ¹³C NMR (125 MHz, CDCl₃) δ = 165.5 (1C, C_q Bz), 137.5, 134.8, 133.2, 133.1, 129.9 (6C, 6 × C_q arom.), 133.4–126.0 (22C, arom.), 83.0 (1C, C-1), 76.5 (1C, C-5), 74.4 (1C, C-4), 73.7 (1C, NAPCH₂), 72.9 (1C, C-3), 72.3 (1C, BnCH₂), 70.1 (1C, C-2), 62.6 (1C, C-6) ppm; ESI-TOF-MS: *m/z* calcd for C₃₇H₃₄NaO₆S, [M + Na]⁺ 629.1968; found: 629.1961.

Phenyl 2,3-di-O-benzyl-4,6-O-(2'-naphthyl)methylidene-1-thio-β-L-gulopyranoside (54). Compound **51** (350 mg, 0.591 mmol) was converted to **54** according to general **Method G**. The crude product was purified by silica gel chromatography (7:3 *n*-hexane/acetone) to give **54** (267 mg, 77%) as a colorless syrup. [α]_D²⁵ + 7.5 (*c* 0.16, CHCl₃); R_f 0.36 (8:2 *n*-hexane/EtOAc); ¹H NMR (400 MHz, CDCl₃) δ = 7.89–7.21 (m, 22H, arom.), 5.63 (s, 1H, H_{ac}), 5.30 (d, *J* = 9.8 Hz, 1H, H-1), 4.83–4.60 (m, 5H, H-6a, 2 × BnCH₂), 4.11 (d, *J* = 3.7 Hz, 1H, H-5), 4.04 (dd, *J* = 1.4 Hz, *J* = 12.4 Hz, 1H, H-6b), 3.95–3.93 (m, 1H, H-4), 3.88 (s, 1H, H-3), 3.85 (dd, *J* = 2.6 Hz, *J* = 10.0 Hz, 1H, H-2) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 138.3, 138.1, 135.4, 133.9, 133.2, 133.0 (6C, 6 × C_q arom.), 132.9–124.2 (22C, arom.), 101.3 (1C, C_{ac}), 83.4 (1C, C-1), 77.3 (1C, C-5), 74.6 (1C, C-4), 74.2 (1C, C-2), 73.8, 72.7 (2C, 2 × BnCH₂), 69.8 (1C, C-6), 67.7 (1C, C-3) ppm; ESI-TOF-MS: *m/z* calcd for C₃₇H₃₄NaO₅S [M + Na]⁺ 613.2019; found: 613.2019.

Phenyl 2,3-di-O-benzoyl-4,6-O-(2'-naphthyl)methylidene-1-thio-β-L-gulopyranoside (55). Compound **52** (870 mg, 1.402 mmol) was converted to **55** according to general **Method G**. The crude product was purified by silica gel chromatography (65:35 *n*-hexane/EtOAc) to give **55** (719 mg, 83%) as a colorless syrup. [α]_D²⁵ + 35.0 (*c* 0.14, CHCl₃); R_f 0.48 (65:35 *n*-hexane/EtOAc); ¹H NMR (400 MHz, CDCl₃) δ = 8.04–7.23 (m, 22H, arom.), 5.82 (s, 1H, H-3), 5.72 (s, 1H, H_{ac}), 5.48 (dd, *J* = 2.7 Hz, *J* = 10.2 Hz, 1H, H-2), 5.40 (d, *J* = 10.2 Hz, 1H, H-1), 4.50 (d, *J* = 12.4 Hz, 1H, H-6a), 4.32 (d, *J* = 2.9 Hz, 1H, H-4), 4.15 (d, *J* = 12.3 Hz, 1H, H-6b), 4.01 (s, 1H, H-5) ppm; ¹³C NMR (125 MHz, CDCl₃) δ = 165.0, 164.7 (2C, 2 × C_q Bz), 134.9, 134.0, 133.0, 130.9, 129.7, 129.5 (6C, 6 × C_q arom.), 134.2–124.2 (22C, arom.), 101.6 (1C, C_{ac}), 82.2 (1C, C-1), 74.2 (1C, C-4), 69.6 (1C, C-3), 69.5 (1C, C-6), 68.5 (1C, C-5), 66.7 (1C, C-2) ppm; ESI-TOF-MS: *m/z* calcd for C₃₇H₃₀NaO₇S [M + Na]⁺ 641.1604; found: 641.1606.

Phenyl 2-O-benzoyl-3-O-benzyl-4,6-O-(2'-naphthyl)methylidene-1-thio-β-L-gulopyranoside (56). Compound **53** (270 mg, 0.445 mmol) was converted to **56** according to general **Method G**. The crude product was purified by silica gel chromatography (85:15 CH₂Cl₂/*n*-hexane) to give **56** (179 mg, 67%) as a colorless syrup. [α]_D²⁵ + 40.9 (*c* 0.21, CHCl₃); R_f 0.63 (85:15 CH₂Cl₂/*n*-hexane); ¹H NMR (400 MHz, CDCl₃) δ = 8.07–7.15 (m, 22H, arom.), 5.61 (s, 1H, H_{ac}), 5.44 (dd, *J* = 2.4 Hz, *J* = 10.3 Hz, 1H, H-1), 5.33 (dt, *J* = 3.2 Hz, *J* = 10.3 Hz, 1H, H-2), 4.58 (s, 2H, BnCH₂), 4.37 (d, *J* = 12.3 Hz, 1H, H-6a), 4.18 (s, 1H, H-3), 4.11 (d, *J* = 3.5 Hz, 1H, H-4), 4.01–3.98 (m, 1H, H-6b), 3.89 (s, 1H, H-5) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 164.9 (1C, C_q Bz), 137.6, 135.2, 133.8, 132.8, 131.6 (6C, 6 × C_q arom.), 133.5–124.1 (22C, arom.) 101.2 (1C, C_{ac}), 81.9 (1C, C-1), 75.0 (1C, C-3), 74.6 (1C, C-4), 73.8 (1C, BnCH₂), 69.5 (1C, C-6), 68.9 (1C, C-2), 67.9 (1C, C-5) ppm; ESI-TOF-MS: *m/z* calcd for C₃₇H₃₂NaO₆S, [M + Na]⁺ 627.1812; found: 627.1822.

Phenyl 2,3-di-O-benzyl-6-O-(2'-naphthyl)methyl-1-thio-β-L-gulopyranoside (57). Compound **54** (250 mg, 0.423 mmol) was converted to **57** according to general **Method H**. The crude product was purified by silica gel chromatography (65:35 *n*-hexane/EtOAc) to give **57** (200 mg, 80%) as a colorless syrup. [α]_D²⁵ + 24.4 (*c* 0.18, CHCl₃); R_f 0.46 (65:35 *n*-hexane/EtOAc); ¹H NMR (400 MHz, CDCl₃) δ = 7.79–7.16 (m, 22H, arom.), 5.26 (d, *J* = 10.0 Hz, 1H, H-1), 4.74–4.48 (m, 6H, 2 × BnCH₂, NAPCH₂), 4.06 (t, *J* = 3.8 Hz, 1H, H-5), 3.96 (s, 1H, H-4), 3.90 (t, *J* = 3.6 Hz, 1H, H-3), 3.83 (dd, *J* = 2.9 Hz, *J* = 9.9 Hz, 1H, H-2), 3.81 (dd, *J* = 3.4 Hz, *J* = 10.3 Hz, 1H, H-6a), 3.75 (dd, *J* = 4.4 Hz, *J* = 10.6 Hz, 1H, H-6b), 3.43 (s, 1H, C-4-OH) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 138.2, 137.9, 134.9, 134.0, 133.1, 132.9 (6C, 6 × C_q arom.), 131.5–125.5 (22C, arom.), 84.7 (1C, C-1), 75.4 (1C, C-2), 74.7 (1C, C-3), 73.9 (1C, C-5), 73.7, 73.3, 72.5 (3C, 2 × BnCH₂, NAPCH₂), 70.9 (1C, C-6), 70.0 (1C, C-4) ppm; ESI-TOF-MS: *m/z* calcd for C₃₇H₃₆NaO₅S [M + Na]⁺ 615.2176; found: 615.2181.

Phenyl 2,3-di-O-benzoyl-6-O-(2'-naphthyl)methyl-1-thio-β-L-gulopyranoside (58). Compound **55** (90 mg, 0.145 mmol) was converted to **58** according to general **Method H**. The crude product was purified by silica gel chromatography (65:35 *n*-hexane/EtOAc) to give **58** (78 mg, 86%) as a colorless syrup. $[\alpha]_D^{25} + 43.5$ (*c* 0.17, CHCl₃); *R_f* 0.34 (7:3 *n*-hexane/EtOAc); ¹H NMR (400 MHz, CDCl₃) $\delta = 7.99\text{--}7.21$ (m, 22H, arom.), 5.77 (t, *J* = 3.5 Hz, 1H, H-3), 5.60 (dd, *J* = 3.3 Hz, *J* = 10.4 Hz, 1H, H-2), 5.36 (d, *J* = 10.4 Hz, 1H, H-1), 4.76 (d, *J* = 3.3 Hz, 2H, NAPCH₂), 4.23 (t, *J* = 4.4 Hz, 1H, H-5), 4.14 (d, *J* = 3.5 Hz, 1H, H-4), 3.91 (d, *J* = 4.7 Hz, 2H, H-6a,b), 3.47 (s, 1H, H-4-OH) ppm; ¹³C NMR (100 MHz, CDCl₃) $\delta = 165.1, 164.9$ (2C, 2 × C_q Bz), 135.0, 133.3, 133.1, 132.5, 129.5, 129.4 (6C, 6 × C_q arom.), 133.6–125.8 (22C, arom.), 83.8 (1C, C-1), 75.5 (1C, C-5), 74.1 (1C, NAPCH₂), 70.7 (1C, C-3), 70.3 (1C, C-6), 69.1 (1C, C-4), 67.1 (1C, C-2) ppm; ESI-TOF-MS: *m/z* calcd for C₃₇H₃₂NaO₇S [M + Na]⁺ 643.1761; found: 643.1762.

Phenyl 2-O-benzoyl-3-O-benzyl-6-O-(2'-naphthyl)methyl-1-thio-β-L-gulopyranoside (59). Compound **56** (428 mg, 0.708 mmol) was converted to **59** according to general **Method H**. The crude product was purified by silica gel chromatography (65:35 *n*-hexane/EtOAc) to give **59** (373 mg, 87%) as a colorless syrup. $[\alpha]_D^{25} + 20.4$ (*c* 0.23, CHCl₃); *R_f* 0.44 (65:35 *n*-hexane/EtOAc); ¹H NMR (500 MHz, CDCl₃) $\delta = 8.08\text{--}7.19$ (m, 22H, arom.), 5.39 (dd, *J* = 2.7 Hz, *J* = 10.4 Hz, 1H, H-2), 5.36 (d, *J* = 10.4 Hz, 1H, H-1), 4.82–4.56 (m, 4H, NAPCH₂, BnCH₂), 4.20 (t, *J* = 4.2 Hz, 1H, H-5), 4.12–4.11 (m, 1H, H-3), 4.03 (t, *J* = 4.1 Hz, 1H, H-4), 3.90 (dd, *J* = 4.1 Hz, *J* = 10.6 Hz, 1H, H-6a), 3.85 (dd, *J* = 4.4 Hz, *J* = 10.6 Hz, 1H, H-6b), 3.23 (d, *J* = 4.3 Hz, 1H, C-4-OH) ppm; ¹³C NMR (100 MHz, CDCl₃) $\delta = 165.1$ (1C, C_q Bz), 137.8, 135.1, 133.1, 132.9, 129.7 (6C, 6 × C_q arom.), 133.2–125.6 (22C, arom.) 83.6 (1C, C-1), 76.5 (1C, C-3), 74.6 (1C, C-5), 73.8, 73.6 (2C, NAPCH₂, BnCH₂), 70.6 (1C, C-6), 69.5 (1C, C-4), 69.1 (1C, C-2) ppm; ESI-TOF-MS: *m/z* calcd for C₃₇H₃₄NaO₆S, [M + Na]⁺ 629.1968; found: 629.1954.

Phenyl 2,3-di-O-benzyl-6-O-(2'-naphthyl)methyl-1-thio-β-L-ribo-hexopyranos-4-uloside (60). Compound **57** (160 mg, 0.270 mmol) was converted to **60** according to general **Method I**. The crude product was purified by silica gel chromatography (7:3 *n*-hexane/EtOAc) to give **60** (107 mg, 67%) as a colorless syrup. $[\alpha]_D^{25} + 1.2$ (*c* 0.17, CHCl₃); *R_f* 0.55 (7:3 *n*-hexane/EtOAc); ¹H NMR (400 MHz, CDCl₃) $\delta = 7.81\text{--}7.17$ (m, 22H, arom.), 5.16 (d, *J* = 2.6 Hz, 1H, H-1), 4.73–4.54 (m, 6H, 2 × BnCH₂, NAPCH₂), 4.46 (d, *J* = 3.5 Hz, 1H, H-3), 4.32–4.29 (m, 1H, H-5), 4.19 (t, *J* = 3.0 Hz, 1H, H-2), 3.88 (qd, *J* = 3.4 Hz, *J* = 10.8 Hz, 2H, H-6a,b) ppm; ¹³C NMR (100 MHz, CDCl₃) $\delta = 206.0$ (1C, C-4), 137.4, 137.3, 135.5, 133.3, 133.1, 132.2 (6C, 6 × C_q arom.), 133.0–125.7 (22C, arom.), 86.4 (1C, C-1), 82.5 (1C, C-5), 82.1 (1C, C-3), 80.1 (1C, C-2), 73.7, 73.3, 72.8 (3C, 2 × BnCH₂, NAPCH₂), 69.6 (1C, C-6) ppm; ESI-TOF-MS: *m/z* calcd for C₃₇H₃₄NaO₅S [M + Na]⁺ 613.2019; found: 613.2011.

Phenyl 2,3-di-O-benzoyl-6-O-(2'-naphthyl)methyl-1-thio-β-L-ribo-hexopyranos-4-uloside (61). Compound **58** (69 mg, 0.112 mmol) was converted to **61** according to general **Method I**. The crude product was purified by silica gel chromatography (7:3 *n*-hexane/EtOAc) to give **61** (50 mg, 73%) as a colorless syrup. $[\alpha]_D^{25} - 17.5$ (*c* 0.12, CHCl₃); *R_f* 0.34 (7:3 *n*-hexane/EtOAc); ¹H NMR (400 MHz, CDCl₃) $\delta = 7.98\text{--}7.24$ (m, 22H, arom.), 6.12 (dd, *J* = 2.8 Hz, *J* = 4.2 Hz, 1H, H-2), 6.07 (d, *J* = 4.2 Hz, 1H, H-3), 5.31 (d, *J* = 2.7 Hz, 1H, H-1), 4.77 (s, 2H, NAPCH₂), 4.51 (t, *J* = 3.8 Hz, 1H, H-5), 4.00 (d, *J* = 3.9 Hz, 2H, H-6a,b) ppm; ¹³C NMR (100 MHz, CDCl₃) $\delta = 201.0$ (1C, C-4), 165.0, 164.7 (2C, 2 × C_q Bz), 135.3, 133.4, 133.2, 131.3, 128.9 (6C, 6 × C_q arom.), 133.9–125.7 (22C, arom.), 85.9 (1C, C-1), 83.4 (1C, C-5), 74.7, 74.4 (2C, C-2, C-3), 73.9 (1C, NAPCH₂), 69.5 (1C, C-6) ppm; ESI-TOF-MS: *m/z* calcd for C₃₇H₃₀NaO₇S [M + Na]⁺ 641.1604; found: 641.1607.

Phenyl 2-O-benzoyl-3-O-benzyl-6-O-(2'-naphthyl)methyl-1-thio-β-L-ribo-hexopyranos-4-uloside (62). Compound **59** (342 mg, 0.563 mmol) was converted to **62** according to general **Method I**. The crude product was purified by silica gel chromatography (7:3 *n*-hexane/EtOAc) to give **62** (196 mg, 58%) as a colorless syrup. $[\alpha]_D^{25} - 16.2$ (*c* 0.08, CHCl₃); *R_f* 0.42 (7:3 *n*-hexane/EtOAc); ¹H NMR (400 MHz, CDCl₃) $\delta = 7.97\text{--}7.16$ (m, 22H, arom.), 5.85 (t, *J* = 4.0 Hz, 1H, H-2), 5.22 (d, *J* = 3.9 Hz, 1H, H-1), 4.67 (d, *J* = 2.3 Hz, 2H, NAPCH₂), 4.55 (d, *J* = 12.2 Hz, 1H, BnCH₂a), 4.46–4.40 (m, 3H, H-3, H-5, BnCH₂b), 3.92 (d, *J* = 3.6 Hz, 2H, H-6) ppm; ¹³C NMR (100 MHz, CDCl₃) $\delta = 203.9$ (1C, C-4), 165.0 (1C, C_q Bz), 136.7, 135.2, 133.2,

133.0, 131.3, 129.1 (6C, 6 × C_q arom.), 133.6–125.6 (22C, arom.), 85.1 (1C, C-1), 82.4 (1C, C-5), 79.3 (1C, C-3), 73.8 (1C, C-2), 73.7, 72.2 (2C, NAPCH₂, BnCH₂), 69.4 (1C, C-6) ppm; ESI-TOF-MS: *m/z* calcd for C₃₇H₃₂NaO₆S, [M + Na]⁺ 627.1812; found: 627.1809.

Phenyl 2,3-di-O-benzyl-6-O-(2'-naphthyl)methyl-1-thio-β-L-allopyranoside (63). Compound **60** (100 mg, 0.169 mmol) was converted to **63** according to general **Method J**. The crude product was purified by silica gel chromatography (65:35 *n*-hexane/EtOAc) to give **63** (98 mg, 98%) as a colorless syrup. [α]_D²⁵ + 10.7 (c 0.29, CHCl₃); R_f 0.33 (65:35 *n*-hexane/EtOAc); ¹H NMR (500 MHz, CDCl₃) δ = 7.78–7.19 (m, 22H, arom.), 5.20 (d, *J* = 7.1 Hz, 1H, H-1), 5.05 (d, *J* = 9.7 Hz, 1H, BnCH₂a), 4.72–4.60 (m, 4H, NAPCH₂, BnCH₂), 4.56 (d, *J* = 10.8 Hz, 1H, BnCH₂b), 4.05 (s, 1H, H-3), 3.83–3.81 (m, 2H, H-4, H-6a), 3.69–3.67 (m, 1H, H-6b), 3.54–3.51 (m, 1H, H-5), 3.44 (d, *J* = 8.3 Hz, 1H, H-2), 2.40 (s, 1H, C-4-OH) ppm; ¹³C NMR (125 MHz, CDCl₃) δ = 138.4, 137.6, 135.9, 134.2, 133.3, 133.0 (6C, 6 × C_q arom.), 131.6–125.8 (22C, arom.), 84.0 (1C, C-1), 78.4 (1C, C-2), 77.5 (1C, C-3), 76.7 (1C, C-5), 75.3, 73.6, 73.1 (3C, 2 × BnCH₂, NAPCH₂), 70.2 (1C, C-6), 68.1 (1C, C-4) ppm; ESI-TOF-MS: *m/z* calcd for C₃₇H₃₆NaO₅S [M + Na]⁺ 615.2176; found: 615.2132.

Phenyl 2,3-di-O-benzoyl-6-O-(2'-naphthyl)methyl-1-thio-β-L-gulopyranoside (58) and *Phenyl 2,3-di-O-benzoyl-6-O-(2'-naphthyl)methyl-1-thio-β-L-allopyranoside (64)*. Compound **61** (27 mg, 0.044 mmol) was converted to **64** according to general **Method J**. The crude product was purified by silica gel chromatography (7:3 *n*-hexane/EtOAc) to give mixture of **58** and **64** (22 mg, 81%, inseparable mixture of the L-gulo and the L-allo configured compounds, ratio of L-gulo (**58**): L-allo (**64**) = 5:1 based on the ¹H NMR spectra (H-3 L-gulo: 5.75 ppm and H-3 L-allo: 6.10 ppm) as a colorless syrup.

Data of **64**: R_f 0.36 (7:3 *n*-hexane/EtOAc); ¹H NMR (400 MHz, CDCl₃) δ = 8.01–7.21 (m, 22H, arom.), 6.10 (t, *J* = 2.9 Hz, 1H, H-3), 5.27 (dd, *J* = 2.8 Hz, *J* = 10.2 Hz, 1H, H-2), 5.10 (d, *J* = 9.9 Hz, 1H, H-1), 4.78–4.67 (m, 2H, NAPCH₂), 4.36 (ddd, *J* = 2.2 Hz, *J* = 5.4 Hz, *J* = 10.3 Hz, 1H, H-5), 3.82 (dd, *J* = 3.3 Hz, *J* = 6.5 Hz, 1H, H-4), 3.79 (dd, *J* = 2.2 Hz, *J* = 11.0 Hz, 1H, H-6a), 3.71 (dd, *J* = 5.5 Hz, *J* = 11.0 Hz, 1H, H-6b), 2.43 (d, *J* = 3.6 Hz, 1H, C-4-OH) ppm; ¹³C NMR (100 MHz, CDCl₃) δ = 133.4–125.9 (22C, arom.), 85.5 (1C, C-1), 75.0 (1C, C-5), 74.1 (1C, NAPCH₂), 70.3 (1C, C-3), 68.9 (1C, C-6), 68.1 (1C, C-4), 67.7 (1C, C-2) ppm; ESI-TOF-MS: *m/z* calcd for C₃₇H₃₂NaO₇S [M + Na]⁺ 643.1761; found: 643.1828.

Phenyl 2-O-benzoyl-3-O-benzyl-6-O-(2'-naphthyl)methyl-1-thio-β-L-allopyranoside (65). Compound **62** (174 mg, 0.287 mmol) was converted to **65** according to general **Method J**. The crude product was purified by silica gel chromatography (7:3 *n*-hexane/EtOAc) to give **65** (155 mg, 89%) as a colorless syrup. [α]_D²⁵ + 25.9 (c 0.17, CHCl₃); R_f 0.38 (7:3 *n*-hexane/EtOAc); ¹H NMR (500 MHz, CDCl₃) δ = 8.09–7.18 (m, 22H, arom.), 5.33 (d, *J* = 10.2 Hz, 1H, H-1), 4.99 (d, *J* = 10.0 Hz, 1H, H-2), 4.83 (d, *J* = 11.4 Hz, 1H, BnCH₂a), 4.75 (s, 2H, NAPCH₂), 4.56 (d, *J* = 11.4 Hz, 1H, BnCH₂b), 4.30 (s, 1H, H-3), 3.94–3.93 (m, 1H, H-5), 3.88 (d, *J* = 10.5 Hz, 1H, H-6a), 3.79–3.72 (m, 2H, H-4, H-6b), 2.44 (d, *J* = 9.3 Hz, 1H, C-4-OH) ppm; ¹³C NMR (125 MHz, CDCl₃) δ = 165.3 (1C, C_q Bz), 137.9, 135.7, 133.4, 133.1, 132.7, 129.6 (6C, 6 × C_q arom.), 133.6–125.8 (22C, arom.), 82.5 (1C, C-1), 77.9 (1C, C-3), 76.9 (1C, C-5), 75.8, 73.8 (2C, NAPCH₂, BnCH₂), 71.7 (1C, C-2), 70.4 (1C, C-6), 68.5 (1C, C-4) ppm; ESI-TOF-MS: *m/z* calcd for C₃₇H₃₄NaO₆S, [M + Na]⁺ 629.1968; found: 629.1964.

3.2.13. Synthesis of L-Galactose and L-Glucose Derivatives from D-Altrose

Phenyl 2-O-benzoyl-4,6-O-(2'-naphthyl)methylidene-1-thio-α-D-mannopyranoside (66). To a solution of compound **29** [91] (2.5 g, 6.096 mmol) in dry CH₃CN (85 mL), we added triethyl-orthobenzoate (2.22 mL, 9.753 mmol, 1.6 equiv.) and stirred for 15 min. After 15 min at that temperature, CSA (425 mg, 1.828 mmol, 0.30 equiv.) was added and the mixture was stirred for 2 h at room temperature. After that, the solvents were evaporated. The residue was dissolved in AcOH (80%, 40 mL) at 0 °C and stirred for 15 min. The reaction mixture was neutralized with NaHCO₃, extracted with CH₂Cl₂ (3 × 100 mL), and the organic phases was washed with H₂O (3 × 50 mL) until neutral pH. The organic layer was dried over MgSO₄ and concentrated. The crude product was purified by silica gel chromatography (7:3 *n*-hexane/acetone) to give **66** (1.81 g, 57%) as a colorless syrup.

$[\alpha]_{\text{D}}^{25}$ -6.2 (c 0.13, CHCl_3); R_f 0.42 (7:3 *n*-hexane/acetone); ^1H NMR (500 MHz, CDCl_3) δ = 8.11–7.24 (m, 17H, arom.), 5.83 (s, 1H, H_{ac}), 5.75 (dd, J = 1.3 Hz, J = 3.5 Hz, 1H, H-2), 5.64 (d, J = 1.0 Hz, 1H, H-1), 4.49 (td, J = 4.9 Hz, J = 9.8 Hz, 1H, H-5), 4.39 (dt, J = 3.7 Hz, J = 9.8 Hz, 1H, H-3), 4.33 (dd, J = 4.9 Hz, J = 10.3 Hz, 1H, H-6a), 4.18 (t, J = 9.7 Hz, 1H, H-4), 3.95 (t, J = 10.3 Hz, 1H, H-6b), 2.56 (dd, J = 4.1 Hz, J = 9.4 Hz, 1H, C-3-OH) ppm; ^{13}C NMR (125 MHz, CDCl_3) δ = 166.1 (1C, C_q Bz), 134.5, 133.9, 133.2, 133.1, 129.6 (5C, $5 \times \text{C}_q$ arom.), 133.7–123.8 (17C, arom.), 102.6 (1C, C_{ac}), 87.2 (1C, C-1), 79.8 (1C, C-4), 74.3 (1C, C-2), 68.7 (1C, C-6), 68.3 (1C, C-3), 64.9 (1C, C-5) ppm; ESI-TOF-MS: m/z calcd for: $\text{C}_{30}\text{H}_{26}\text{NaO}_6\text{S}$ $[\text{M} + \text{Na}]^+$ 537.1342; found: 537.1348.

Phenyl 2-O-benzoyl-4,6-O-(2'-naphthyl)methylidene-1-thio- α -D-altropyranoside (67). Compound **66** (5.68 g, 11.05 mmol) was converted to **3-ulose** according to general Method I. The crude product was purified by silica gel chromatography (6:4 *n*-hexane/EtOAc) to give the **3-ulose** derivative (4.37 g, 77%) as a colorless syrup. $[\alpha]_{\text{D}}^{25}$ +112.0 (c 0.15, CHCl_3); R_f 0.39 (7:3 *n*-hexane/EtOAc); ^1H NMR (400 MHz, CDCl_3) δ = 8.15–7.20 (m, 17H, arom.), 5.92 (s, 1H, H-1), 5.81 (s, 1H, H_{ac}), 5.54 (s, 1H, H-2), 4.98 (d, J = 9.7 Hz, 1H, H-4), 4.77–4.75 (m, 1H, H-5), 4.41–4.30 (m, 1H, H-6a), 4.05 (t, J = 10.0 Hz, 1H, H-6b) ppm; ^{13}C NMR (100 MHz, CDCl_3) δ = 193.4 (1C, C-3), 164.8 (1C, C_q Bz), 133.8, 133.7, 132.9, 131.4 (5C, $5 \times \text{C}_q$ arom.), 134.1–123.8 (17C, arom.), 102.2 (1C, C_{ac}), 88.6 (1C, C-1), 81.9 (1C, C-4), 78.6 (1C, C-2), 69.1 (1C, C-6), 68.1 (1C, C-5) ppm; ESI-TOF-MS: m/z calcd for: $\text{C}_{30}\text{H}_{24}\text{NaO}_6\text{S}$ $[\text{M} + \text{Na}]^+$ 535.1186; found: 535.1210.

To the solution of the **3-ulose** compound (4.44 g, 8.669 mmol) in dry MeOH (53.6 mL), NaBH_4 (492 mg, 13.00 mmol, 1.5 equiv.) was added and the reaction mixture was stirred for 1 h at room temperature. After 1 h the mixture was neutralized with 60% AcOH (6 mL) and concentrated, then the residue was coevaporated with MeOH (3×100 mL). The crude product was purified by silica gel chromatography (CH_2Cl_2) to give **67** (2.61 g, 58%) as a white foam and **66** (710 mg, 16%) as a colorless syrup.

Data of **67**: $[\alpha]_{\text{D}}^{25}$ +167.0 (c 0.10, CHCl_3); R_f 0.40 (CH_2Cl_2); ^1H NMR (500 MHz, CDCl_3) δ = 8.08–7.25 (m, 17H, arom.), 5.90 (s, 1H, H_{ac}), 5.62 (d, J = 3.2 Hz, 1H, H-2), 5.55 (s, 1H, H-1), 4.93 (td, J = 5.1 Hz, J = 10.1 Hz, 1H, H-5), 4.44 (dd, J = 5.1 Hz, J = 10.3 Hz, 1H, H-6a), 4.38 (s, 1H, H-3), 4.17 (dd, J = 2.9 Hz, J = 9.8 Hz, 1H, H-4), 3.97 (t, J = 10.4 Hz, 1H, H-6b), 2.58 (d, J = 1.7 Hz, 1H, C-3-OH) ppm; ^{13}C NMR (100 MHz, CDCl_3) δ = 165.0 (1C, C_q Bz), 136.1, 134.5, 133.9, 133.0, 129.3 (5C, $5 \times \text{C}_q$ arom.), 133.7–123.8 (17C, arom.), 102.5 (1C, C_{ac}), 86.3 (1C, C-1), 77.4 (1C, C-4), 74.1 (1C, C-2), 69.1 (1C, C-6), 66.9 (1C, C-3), 59.6 (1C, C-5) ppm; ESI-TOF-MS: m/z calcd for: $\text{C}_{30}\text{H}_{26}\text{NaO}_6\text{S}$ $[\text{M} + \text{Na}]^+$ 537.1342; found: 537.1389.

Phenyl 2,3-di-O-benzyl-4,6-O-(2'-naphthyl)methylidene-1-thio- α -D-altropyranoside (68). To the solution of compound **67** (888 mg, 1.728 mmol) in MeOH (21 mL), NaOMe (55 mg) was added, and the reaction mixture was stirred for 24 h at room temperature. After 24 h the reaction mixture was neutralized by Amberlite IR-120 (H^+) ion-exchange resin, then it was filtered, washed with MeOH, and concentrated. The crude product was reacted in the further reaction without purification (R_f 0.35 (6:4 *n*-hexane/EtOAc)). To a solution of the crude product (709 mg, 1.728 mmol), dry DMF (7.3 mL) at 0 °C NaH (60%, 173 mg, 4.320 mmol, 1.25 equiv./-OH) was added in portions. After 30 min stirring at this temperature, BnBr (513 μL , 4.320 mmol, 1.25 equiv./-OH) was added, and the reaction mixture was allowed to warm up to room temperature and stirred for 24 h. After completion of the reaction, MeOH (20 mL) was added. The reaction mixture was stirred for 15 min, then the solvents were evaporated. The residue was diluted with CH_2Cl_2 (500 mL), washed with H_2O (3×100 mL), dried over MgSO_4 , filtered, and concentrated. The crude product was purified by silica gel chromatography (8:2 *n*-hexane/EtOAc) to give **68** (796 mg, 78% for two steps) as a yellow syrup. $[\alpha]_{\text{D}}^{25}$ -145.0 (c 0.12, CHCl_3); R_f 0.49 (8:2 *n*-hexane/EtOAc); ^1H NMR (500 MHz, CDCl_3) δ = 7.96–7.25 (m, 22H, arom.), 5.75 (s, 1H, H_{ac}), 5.49 (s, 1H, H-1), 4.88–4.85 (m, 2H, H-5, BnCH_2a), 4.74 (d, J = 12.5 Hz, 1H, BnCH_2b), 4.61 (d, J = 11.9 Hz, 1H, BnCH_2a), 4.52 (d, J = 11.9 Hz, 1H, BnCH_2b), 4.37 (dd, J = 5.0 Hz, J = 10.0 Hz, 1H, H-6a), 4.18 (d, J = 9.5 Hz, 1H, H-4), 4.03–4.01 (m, 2H, H-2, H-3), 3.89 (t, J = 10.3 Hz, 1H, H-6b) ppm; ^{13}C NMR (125 MHz, CDCl_3) δ = 138.5, 137.4, 137.3, 135.3, 133.8,

133.1 (6C, 6 × C_q arom.), 130.8–124.0 (22C, arom.), 102.5 (1C, C_{ac}), 86.4 (1C, C-1), 78.9 (1C, C-2), 77.7 (1C, C-4), 73.5 (1C, C-3), 73.2, 72.4 (2C, 2 × BnCH₂), 69.4 (1C, C-6), 60.3 (1C, C-5) ppm; ESI-TOF-MS: *m/z* calcd for: C₃₇H₃₄NaO₅S [M + Na]⁺ 613.2019; found: 613.2014.

Phenyl 2,3-di-O-benzoyl-4,6-O-(2'-naphthyl)methylidene-1-thio-α-D-altropyranoside (69). To a stirred solution of compound **67** (892 mg, 1.735 mmol) in dry pyridine (4.7 mL), BzCl (252 μL, 2.169 mmol, 1.25 equiv.) was added at 0 °C and the reaction mixture was stirred for 24 h at room temperature. After 24 h the mixture was diluted with CH₂Cl₂ (100 mL), washed with H₂O (25 mL), 1M aqueous solution of H₂SO₄ (2 × 25 mL), H₂O (25 mL), saturated aqueous solution of NaHCO₃ (2 × 25 mL), and H₂O (25 mL) until neutral pH. The organic layer was separated, dried over MgSO₄, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel chromatography (7:3 → 8:2 CH₂Cl₂/*n*-hexane) to give **69** (887 mg, 83%) as a colorless syrup. [α]_D²⁵ + 174.2 (c 0.12, CHCl₃); R_f 0.49 (7:3 CH₂Cl₂/*n*-hexane); ¹H NMR (500 MHz, CDCl₃) δ = 8.34–7.23 (m, 22H, arom.), 5.88 (s, 1H, H_{ac}), 5.83 (s, 1H, H-3), 5.72 (s, 1H, H-2), 5.61 (s, 1H, H-1), 5.05 (td, *J* = 5.2 Hz, *J* = 9.9 Hz, 1H, H-5), 4.47 (dd, *J* = 5.0 Hz, *J* = 10.3 Hz, 1H, H-6a), 4.38 (d, *J* = 9.6 Hz, 1H, H-4), 3.99 (t, *J* = 10.4 Hz, 1H, H-6b) ppm; ¹³C NMR (125 MHz, CDCl₃) δ = 165.4, 164.9 (2C, 2 × C_q Bz), 135.2, 134.5, 133.8, 133.0, 129.5, 129.2 (6C, 6 × C_q arom.), 133.9–123.7 (22C, arom.), 102.3 (1C, C_{ac}), 86.5 (1C, C-1), 75.6 (1C, C-4), 72.6 (1C, C-2), 69.3 (1C, C-6), 67.3 (1C, C-3), 60.7 (1C, C-5) ppm; ESI-TOF-MS: *m/z* calcd for: C₃₇H₃₀NaO₇S [M + Na]⁺ 641.1604; found: 641.1608.

Phenyl 2,3-di-O-benzyl-4-O-(2'-naphthyl)methyl-1-thio-α-D-altropyranoside (70). Compound **68** (750 mg, 1.270 mmol) was converted to **70** according to general **Method D**. The crude product was purified by silica gel chromatography (65:35 *n*-hexane/EtOAc) to give **70** (660 mg, 88%) as a colorless syrup. [α]_D²⁵ + 140.0 (c 0.17, CHCl₃); R_f 0.48 (65:35 *n*-hexane/EtOAc); ¹H NMR (500 MHz, CDCl₃) δ = 7.83–7.12 (m, 22H, arom.), 5.44 (s, 1H, H-1), 4.73–4.33 (m, 7H, H-5, NAPCH₂, 2 × BnCH₂), 3.96–3.94 (m, 2H, H-2, H-4), 3.93–3.88 (m, 2H, H-6a,b), 3.83 (s, 1H, H-4), 1.89 (s, 1H, C-6-OH) ppm; ¹³C NMR (125 MHz, CDCl₃) δ = 138.0, 137.5, 137.4, 135.6, 133.4, 133.1 (6C, 6 × C_q arom.), 131.1–126.0 (22C, arom.), 86.2 (1C, C-1), 77.4 (1C, C-2), 72.8 (1C, C-4), 72.6 (1C, C-3), 72.2, 72.2, 71.7 (3C, NAPCH₂, 2 × BnCH₂), 68.6 (1C, C-5), 62.7 (1C, C-6) ppm; ESI-TOF-MS: *m/z* calcd for: C₃₇H₃₆NaO₅S [M + Na]⁺ 615.2176; found: 615.2173.

Phenyl 2,3-di-O-benzoyl-4-O-(2'-naphthyl)methyl-1-thio-α-D-altropyranoside (71). Compound **69** (823 mg, 1.331 mmol) was converted to **71** according to general **Method D**. The crude product was purified by silica gel chromatography (65:35 *n*-hexane/EtOAc) to give **71** (728 mg, 88%) as a colorless syrup. [α]_D²⁵ + 131.8 (c 0.11, CHCl₃); R_f 0.49 (6:4 *n*-hexane/EtOAc); ¹H NMR (500 MHz, CDCl₃) δ = 8.35–7.25 (m, 22H, arom.), 5.94 (s, 1H, H-3), 5.59 (d, *J* = 3.1 Hz, 1H, H-2), 5.56 (s, 1H, H-1), 4.93 (d, *J* = 11.5 Hz, 1H, NAPCH₂a), 4.77–4.72 (m, 2H, H-5, NAPCH₂b), 4.14 (dd, *J* = 2.7 Hz, *J* = 9.9 Hz, 1H, H-4), 3.97 (d, *J* = 11.6 Hz, 1H, H-6a), 3.91–3.87 (m, 1H, H-6b), 1.86 (t, *J* = 6.2 Hz, 1H, C-6-OH) ppm; ¹³C NMR (125 MHz, CDCl₃) δ = 165.6, 164.9 (2C, 2 × C_q Bz), 135.4, 134.7, 133.3, 133.2, 129.5, 129.1 (6C, 6 × C_q arom.), 133.7–126.2 (22C, arom.), 86.1 (1C, C-1), 72.5 (1C, C-2), 71.5 (1C, NAPCH₂), 70.5 (1C, C-4), 68.6 (1C, C-5), 66.1 (1C, C-3), 62.5 (1C, C-6) ppm; ESI-TOF-MS: *m/z* calcd for: C₃₇H₃₂NaO₇S [M + Na]⁺ 643.1761; found: 643.1821.

Phenyl 2,3-di-O-benzyl-6-deoxy-6-iodo-4-O-(2'-naphthyl)methyl-1-thio-α-D-altropyranoside (72). Compound **70** (650 mg, 1.095 mmol) was converted to **72** according to general **Method A**. The crude product was purified by silica gel chromatography (4:6 → 8:2 CH₂Cl₂/*n*-hexane) to give **72** (665 mg, 87%) as a white foam. [α]_D²⁵ + 93.3 (c 0.12, CHCl₃); R_f 0.57 (7:3 CH₂Cl₂/*n*-hexane); ¹H NMR (500 MHz, CDCl₃) δ = 7.85–7.19 (m, 22H, arom.), 5.51 (s, 1H, H-1), 4.72–4.48 (m, 5H, NAPCH₂, 2 × BnCH₂a, BnCH₂b), 4.40 (t, *J* = 6.8 Hz, 1H, H-5), 4.36 (d, *J* = 12.2 Hz, 1H, BnCH₂b), 4.01 (d, *J* = 1.9 Hz, 1H, H-2), 3.81–3.79 (m, 2H, H-3, H-4), 3.64–3.62 (m, 1H, H-6a), 3.47 (dd, *J* = 6.5 Hz, *J* = 10.6 Hz, 1H, H-6b) ppm; ¹³C NMR (125 MHz, CDCl₃) δ = 137.8, 137.7, 137.6, 135.3, 133.3, 133.1 (6C, 6 × C_q arom.), 131.0–126.1 (22C, arom.), 86.2 (1C, C-1), 77.2 (1C, C-2), 76.7 (1C, C-3), 72.5, 72.0, 71.6 (3C, NAPCH₂,

2 × BnCH₂), 72.1 (1C, C-4), 67.5 (1C, C-5), 8.7 (1C, C-6) ppm; ESI-TOF-MS: *m/z* calcd for: C₃₇H₃₅INaO₄S [M + Na]⁺ 725.1193; found: 725.1195.

Phenyl 2,3-di-O-benzoyl-6-deoxy-6-iodo-4-O-(2'-naphthyl)methyl-1-thio-α-D-altropyranoside (73). Compound **71** (676 mg, 1.089 mmol) was converted to **73** according to general **Method A**. The crude product was purified by silica gel chromatography (1:1 → 8:2 CH₂Cl₂/*n*-hexane) to give **73** (759 mg, 95%) as a colorless syrup. [α]_D²⁵ + 99.2 (c 0.13, CHCl₃); R_f 0.46 (8:2 *n*-hexane/EtOAc); ¹H NMR (500 MHz, CDCl₃) δ = 8.34–7.26 (m, 22H, arom.), 5.95 (s, 1H, H-3), 5.64 (s, 1H, H-2), 5.59 (s, 1H, H-1), 4.96 (d, *J* = 11.1 Hz, 1H, NAPCH₂a), 4.72 (d, *J* = 11.1 Hz, 1H, NAPCH₂b), 4.46–4.43 (m, 1H, H-5), 4.02 (d, *J* = 9.2 Hz, 1H, H-4), 3.64 (d, *J* = 10.6 Hz, 1H, H-6a), 3.52 (dd, *J* = 5.7 Hz, *J* = 10.5 Hz, 1H, H-6b) ppm; ¹³C NMR (125 MHz, CDCl₃) δ = 165.5, 164.8 (2C, 2 × C_q Bz), 135.6, 134.4, 133.3, 129.3, 129.1 (6C, 6 × C_q arom.), 133.7–126.3 (22C, arom.), 86.3 (1C, C-1), 74.5 (1C, C-4), 72.4 (1C, C-2), 71.7 (1C, NAPCH₂), 67.3 (1C, C-5), 65.6 (1C, C-3), 8.3 (1C, C-6) ppm; ESI-TOF-MS: *m/z* calcd for: C₃₇H₃₁INaO₆S [M + Na]⁺ 753.0778; found: 753.0792.

Phenyl 2,3-di-O-benzyl-4-O-(2'-naphthyl)methyl-1-thio-α-D-arabino-hex-5-enopyranoside (74).

Reaction I: Compound **72** (218 mg, 0.310 mmol) was converted to **74** according to general **Method E**. The crude product was purified by silica gel chromatography (7:3 CH₂Cl₂/*n*-hexane) to give **74** (151 mg, 85%) as a colorless syrup.

Reaction II: Compound **72** (201 mg, 0.286 mmol) was converted to **74** according to general **Method F**. The crude product was purified by silica gel chromatography (7:3 CH₂Cl₂/*n*-hexane) to give **72** (31 mg, 19%) as a colorless syrup and **74** (85 mg, 52%) as a colorless syrup.

Data of **74**: [α]_D²⁵ + 50.8 (c 0.12, CHCl₃); R_f 0.47 (8:2 CH₂Cl₂/*n*-hexane); ¹H NMR (500 MHz, CDCl₃) δ = 7.85–7.20 (m, 22H, arom.), 4.96 (d, *J* = 7.5 Hz, 1H, H-1), 4.91 (s, 1H, H-6a), 4.91–4.59 (m, 6H, NAPCH₂, 2 × BnCH₂), 4.53 (s, 1H, H-6b), 4.13–4.10 (m, 2H, H-2, H-4), 3.67 (dd, *J* = 3.1 Hz, *J* = 8.0 Hz, 1H, H-3) ppm; ¹³C NMR (125 MHz, CDCl₃) δ = 153.9 (1C, C-5), 138.2, 138.1, 135.4, 134.3, 133.4, 133.1 (6C, 6 × C_q arom.), 131.9–126.0 (22C, arom.), 100.2 (1C, C-6), 88.6 (1C, C-1), 80.0 (1C, C-3), 77.1 (1C, C-2), 74.9, 72.1, 69.9 (3C, NAPCH₂, 2 × BnCH₂), 73.3 (1C, C-4) ppm; ESI-TOF-MS: *m/z* calcd for: C₃₇H₃₄NaO₄S [M + Na]⁺ 597.2070; found: 597.2051.

Phenyl 2,3-di-O-benzyl-4-O-(2'-naphthyl)methyl-1-thio-α-D-arabino-hex-5-enopyranoside (74) and *8-N-[phenyl 2,3-di-O-benzyl-6-deoxy-6-yl-4-O-(2'-naphthyl)methyl-1-thio-α-D-altropyranoside]-1,8-diazabicyclo(5.4.0)undec-7-ene-iodide (75)*. Compound **72** (215 mg, 0.306 mmol) was converted to **74** according to general **Method B**. The crude product was purified by silica gel chromatography (7:3 CH₂Cl₂/*n*-hexane → 95:5 CH₂Cl₂/MeOH) to give **74** (102 mg, 58%) as a colorless syrup and **75** (107 mg, 41%) as a light yellow syrup.

Data of **75**: [α]_D²⁵ + 120.8 (c 0.13, CHCl₃); R_f 0.44 (7:3 CH₂Cl₂/MeOH); ¹H NMR (500 MHz, CDCl₃) δ = 7.86–7.17 (m, 22H, arom.), 5.51 (s, 1H, H-1), 4.69–4.41 (m, 7H, H-5, NAPCH₂, 2 × BnCH₂), 4.00 (dd, *J* = 1.6 Hz, *J* = 15.3 Hz, 1H, H-6a), 3.94 (d, *J* = 3.4 Hz, 1H, H-2), 3.86 (t, *J* = 3.0 Hz, 1H, H-3), 3.68 (dd, *J* = 2.8 Hz, *J* = 9.9 Hz, 1H, H-4), 3.64–3.39 (m, 7H, H-6b, 3 × NCH₂ DBU), 2.84–2.68 (m, 2H, CH₂ DBU), 1.84–1.80 (m, 2H, CH₂ DBU), 1.61–1.47 (m, 6H, 3 × CH₂ DBU) ppm; ¹³C NMR (125 MHz, CDCl₃) δ = 167.2 (1C, C_q DBU), 137.2, 137.0, 136.1, 134.4, 133.0, 132.9 (6C, 6 × C_q arom.), 129.4–125.9 (22C, arom.), 84.5 (1C, C-1), 76.4 (1C, C-2), 73.4 (1C, C-4), 72.5, 72.3, 70.9 (3C, NAPCH₂, 2 × BnCH₂), 71.0 (1C, C-3), 66.5 (1C, C-5), 55.5 (1C, C-6), 55.0, 49.4, 48.0 (3C, 3 × NCH₂ DBU), 28.9, 28.1, 25.6, 22.5, 19.7 (5C, 5 × CH₂ DBU) ppm; UHR ESI-QTOF: *m/z* calcd for C₄₆H₅₁N₂O₄S [M]⁺ 727.3564; found: 727.3572.

Phenyl 4-O-(2'-naphthyl)methyl-1-thio-α-D-arabino-hex-5-enopyranoside (76) and *Phenyl 2,6-anhydro-4-O-(2'-naphthyl)methyl-1-thio-α-D-altropyranoside (77)*. Compound **73** (254 mg, 0.347 mmol) was converted to **76** according to general **Method E**. The crude product was purified by silica gel chromatography (97:3 → 9:1 CH₂Cl₂/acetone) to give **76** (60 mg, 43%) as a white foam and **77** (30 mg, 22%) as a white foam.

Data of **76**: [α]_D²⁵ + 34.3 (c 0.14, CHCl₃); R_f 0.17 (97:3 CH₂Cl₂/acetone); ¹H NMR (500 MHz, CDCl₃) δ = 7.81–7.21 (m, 12H, arom.), 4.94 (s, 1H, H-6a), 4.77 (d, *J* = 11.7 Hz,

1H, NAPCH₂a), 4.64 (d, *J* = 9.3 Hz, 1H, H-1), 4.55 (s, 1H, H-6b), 4.43 (d, *J* = 11.7 Hz, 1H, NAPCH₂b), 4.03 (d, *J* = 3.5 Hz, 1H, H-4), 3.87 (t, *J* = 9.1 Hz, 1H, H-2), 3.65 (d, *J* = 6.3 Hz, 1H, H-3), 3.06 (s, 2H, C-2-OH, C-3-OH) ppm; ¹³C NMR (125 MHz, CDCl₃) δ = 154.0 (1C, C-5), 134.9, 133.3, 133.1, 132.0 (4C, 4 \times C_q arom.), 132.7–125.9 (12C, arom.), 102.0 (1C, C-6), 88.9 (1C, C-1), 76.7 (1C, C-4), 73.6 (1C, C-3), 70.1 (1C, NAPCH₂), 69.5 (1C, C-2) ppm; ESI-TOF-MS: *m/z* calcd for: C₂₃H₂₂NaO₄S [M + Na]⁺ 417.1131; found: 417.1131.

Data of **77**: [α]_D²⁵ +227.3 (*c* 0.12, CHCl₃); *R*_f 0.54 (97:3 CH₂Cl₂/acetone); ¹H NMR (500 MHz, CDCl₃) δ = 7.86–7.23 (m, 12H, arom.), 5.72 (t, *J* = 1.5 Hz, 1H, H-1), 4.93 (s, 2H, NAPCH₂), 4.28–4.24 (m, 1H, H-5), 4.18 (dd, *J* = 2.7 Hz, *J* = 10.4 Hz, 1H, H-6a), 4.07 (s, 1H, H-3), 4.05 (dd, *J* = 1.9 Hz, *J* = 3.6 Hz, 1H, H-2), 3.88 (dd, *J* = 2.0 Hz, *J* = 8.8 Hz, 1H, H-4), 3.73 (s, 1H, C-3-OH), 3.71 (d, *J* = 4.2 Hz, 1H, H-6b) ppm; ¹³C NMR (125 MHz, CDCl₃) δ = 136.5, 134.6, 133.3, 133.2 (4C, 4 \times C_q arom.), 131.2–125.8 (12C, arom.), 85.8 (1C, C-1), 72.5 (1C, NAPCH₂), 72.2 (1C, C-4), 70.2 (1C, C-2), 68.0 (1C, C-3), 66.3 (1C, C-6), 66.1 (1C, C-5) ppm; ESI-TOF-MS: *m/z* calcd for: C₂₃H₂₂NaO₄S [M + Na]⁺ 417.1131; found: 417.1144.

Phenyl 2,3-di-O-benzoyl-4-O-(2'-naphthyl)methyl-1-thio- α -D-arabino-hex-5-enopyranoside (78). To a stirred solution of compound **76** (60 mg, 0.150 mmol) in dry pyridine (1.0 mL), BzCl (52 μ L, 0.449 mmol, 1.5 equiv.) was added at 0 °C and the reaction mixture was stirred for 24 h at room temperature. After 24 h the mixture was diluted with CH₂Cl₂ (50 mL), washed with H₂O (15 mL), 1M aqueous solution of H₂SO₄ (2 \times 15 mL), H₂O (15 mL), saturated aqueous solution of NaHCO₃ (2 \times 15 mL), and H₂O (15 mL) until neutral pH. The organic layer was separated, dried over MgSO₄, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel chromatography (8:2 CH₂Cl₂/*n*-hexane) to give **78** (57 mg, 63%) as a colorless syrup. [α]_D²⁵ + 10.8 (*c* 0.12, CHCl₃); *R*_f 0.45 (7:3 CH₂Cl₂/*n*-hexane); ¹H NMR (500 MHz, CDCl₃) δ = 8.08–7.23 (m, 22H, arom.), 5.96 (dd, *J* = 7.2 Hz, *J* = 7.8 Hz, 1H, H-2), 5.48 (dd, *J* = 3.2 Hz, *J* = 8.0 Hz, 1H, H-3), 5.25 (d, *J* = 7.0 Hz, 1H, H-1), 5.05 (s, 1H, H-6a), 4.87 (d, *J* = 12.6 Hz, 1H, NAPCH₂a), 4.81 (s, 1H, H-6b), 4.63 (d, *J* = 12.6 Hz, 1H, NAPCH₂b), 4.43 (d, *J* = 3.2 Hz, 1H, H-4) ppm; ¹³C NMR (125 MHz, CDCl₃) δ = 165.8, 165.1 (2C, 2 \times C_q Bz), 152.8 (1C, C-5), 135.0, 133.3, 133.1, 129.4 (6C, 6 \times C_q arom.), 133.5–125.7 (22C, arom.), 101.3 (1C, C-6), 87.6 (1C, C-1), 73.1 (1C, C-4), 72.1 (1C, C-3), 70.3 (1C, NAPCH₂), 69.3 (1C, C-2) ppm; ESI-TOF-MS: *m/z* calcd for: C₃₇H₃₀NaO₆S [M + Na]⁺ 625.1655; found: 625.1654.

Phenyl 2,3-di-O-benzoyl-4-O-(2'-naphthyl)methyl-1-thio- α -D-arabino-hex-5-enopyranoside (78) and 8-N-[phenyl 2,3-di-O-benzoyl-6-deoxy-6-yl-4-O-(2'-naphthyl)methyl-1-thio- α -D-altropyranoside]-1,8-diazabicyclo(5.4.0)undec-7-ene-iodide (79). Compound **73** (257 mg, 0.351 mmol) was converted to **78** according to general **Method B**. The crude product was purified by silica gel chromatography (7:3 CH₂Cl₂/*n*-hexane \rightarrow 9:1 CH₂Cl₂/MeOH) to give **78** (105 mg, 50%) as a white foam and **79** (130 mg, 42%) as a light yellow syrup.

Data of **79**: [α]_D²⁵ + 75.0 (*c* 0.16, CHCl₃); *R*_f 0.54 (9:1 CH₂Cl₂/MeOH); ¹H NMR (500 MHz, CDCl₃) δ = 8.31–7.27 (m, 22H, arom.), 5.96 (s, 1H, H-3), 5.72 (s, 1H, H-1), 5.58 (d, *J* = 3.1 Hz, 1H, H-2), 4.92 (d, *J* = 11.2 Hz, 1H, NAPCH₂a), 4.77 (d, *J* = 11.2 Hz, 1H, NAPCH₂b), 4.71 (t, *J* = 9.6 Hz, 1H, H-5), 4.16 (d, *J* = 15.5 Hz, 1H, H-6a), 3.99 (dd, *J* = 2.5 Hz, *J* = 9.8 Hz, 1H, H-4), 3.76 (dd, *J* = 9.7 Hz, *J* = 15.7 Hz, 1H, H-6b), 3.67–3.49 (m, 6H, 3 \times NCH₂ DBU), 2.87–2.74 (m, 2H, CH₂ DBU), 1.92–1.83 (m, 2H, CH₂ DBU), 1.66–1.56 (m, 6H, 3 \times CH₂ DBU) ppm; ¹³C NMR (125 MHz, CDCl₃) δ = 167.5 (1C, C_q DBU), 165.0, 164.7 (2C, 2 \times C_q Bz), 134.3, 133.6, 133.0, 132.9, 128.8, 128.3 (6C, 6 \times C_q arom.), 133.8–126.2 (22C, arom.), 84.6 (1C, C-1), 71.6 (1C, C-4), 71.2 (1C, C-2), 71.1 (1C, NAPCH₂), 67.3 (1C, C-5), 64.9 (1C, C-3), 55.2 (1C, C-6), 55.7, 49.4, 48.4 (3C, 3 \times NCH₂ DBU), 29.1, 28.2, 25.7, 22.7, 19.8 (5C, 5 \times CH₂ DBU) ppm; UHR ESI-QTOF: *m/z* calcd for C₄₆H₄₇N₂O₆S [M]⁺ 755.3149; found: 755.3154.

Phenyl 2,3-di-O-benzoyl-4-O-(2'-naphthyl)methyl-1-thio- α -D-arabino-hex-5-enopyranoside (78) and 1,5-anhydro-2-O-benzoyl-3,6-dideoxy-4-O-(2'-naphthyl)methyl-3-S-phenyl-3-thio- α -D-erythro-hex-1,5-dienytol (47). Compound **73** (234 mg, 0.320 mmol) was converted to **78** according to general **Method F**. The crude product was purified by silica gel chromatography (7:3 CH₂Cl₂/*n*-hexane) to give **78** (103 mg, 53%) as a white foam and **47** (20 mg, 10%) as a colorless syrup.

Phenyl 2,3-di-O-benzyl-4-O-(2'-naphthyl)methyl-1-thio-β-L-galactopyranoside (80). Compound **74** (143 mg, 0.249 mmol) was converted to **80** according to general **Method C**. The crude product was purified by silica gel chromatography (55:45 *n*-hexane/EtOAc) to give **80** (100 mg, 68%) as a colorless syrup. $[\alpha]_D^{25} + 7.0$ (*c* 0.10, CHCl₃); *R*_f 0.41 (55:45 *n*-hexane/EtOAc); ¹H NMR (400 MHz, CDCl₃) $\delta = 7.84\text{--}7.17$ (m, 22H, arom.), 5.12–4.65 (m, 6H, NAPCH₂, 2 × BnCH₂), 4.66 (d, *J* = 9.6 Hz, 1H, H-1), 3.99 (t, *J* = 9.4 Hz, 1H, H-2), 3.88–3.84 (m, 2H, H-4, H-6a), 3.61 (dd, *J* = 2.7 Hz, *J* = 9.2 Hz, 1H, H-3), 3.53–3.49 (m, 1H, H-6b), 3.45–3.42 (m, 1H, H-5), 1.84 (d, *J* = 4.7 Hz, 1H, C-6-OH) ppm; ¹³C NMR (100 MHz, CDCl₃) $\delta = 138.3, 138.2, 135.8, 134.1, 133.2, 133.1$ (6C, 6 × C_q arom.), 131.6–126.2 (22C, arom.), 87.8 (1C, C-1), 84.4 (1C, C-3), 79.0 (1C, C-5), 77.6 (1C, C-2), 75.8, 74.4, 73.2 (3C, NAPCH₂, 2 × BnCH₂), 73.4 (1C, C-4), 62.4 (1C, C-6) ppm; ESI-TOF-MS: *m/z* calcd for: C₃₇H₃₆NaO₅S [M + Na]⁺ 615.2176; found: 615.2189.

Phenyl 2,3-di-O-benzoyl-4-O-(2'-naphthyl)methyl-1-thio-β-L-galactopyranoside (81). Compound **78** (193 mg, 0.319 mmol) was converted to **81** according to general **Method C**. The crude product was purified by silica gel chromatography (55:45 *n*-hexane/EtOAc) to give **81** (152 mg, 76%) as a colorless syrup. $[\alpha]_D^{25} - 68.3$ (*c* 0.12, CHCl₃); *R*_f 0.40 (55:45 *n*-hexane/EtOAc); ¹H NMR (500 MHz, CDCl₃) $\delta = 7.98\text{--}7.26$ (m, 22H, arom.), 5.93 (t, *J* = 9.9 Hz, 1H, H-2), 5.38 (d, *J* = 9.9 Hz, 1H, H-3), 4.97 (d, *J* = 9.9 Hz, 1H, H-1), 4.90 (d, *J* = 11.8 Hz, 1H, NAPCH₂a), 4.68 (d, *J* = 11.8 Hz, 1H, NAPCH₂b), 4.24 (s, 1H, H-4), 3.98–3.95 (m, 1H, H-6a), 3.81 (t, *J* = 5.6 Hz, 1H, H-5), 3.65–3.63 (m, 1H, H-6b), 1.73 (d, *J* = 6.0 Hz, 1H, C-6-OH) ppm; ¹³C NMR (125 MHz, CDCl₃) $\delta = 166.0, 165.4$ (2C, 2 × C_q Bz), 134.9, 133.2, 133.1, 132.8, 129.7, 129.0 (6C, 6 × C_q arom.), 133.6–126.1 (22C, arom.), 86.7 (1C, C-1), 79.3 (1C, C-5), 76.1 (1C, C-3), 75.0 (1C, NAPCH₂), 74.0 (1C, C-4), 68.6 (1C, C-2), 62.1 (1C, C-6) ppm; ESI-TOF-MS: *m/z* calcd for: C₃₇H₃₂NaO₇S [M + Na]⁺ 643.1761; found: 643.1768.

Phenyl 2,3-di-O-benzyl-4,6-O-(2'-naphthyl)methylidene-1-thio-β-L-galactopyranoside (82). Compound **80** (85 mg, 0.144 mmol) was converted to **82** according to general **Method G**. The crude product was purified by silica gel chromatography (CH₂Cl₂) to give **82** (68 mg, 80%) as a colorless syrup. $[\alpha]_D^{25} - 30.0$ (*c* 0.12, CHCl₃); *R*_f 0.47 (6:4 *n*-hexane/EtOAc); ¹H NMR (500 MHz, CDCl₃) $\delta = 7.98\text{--}7.14$ (m, 22H, arom.), 5.61 (s, 1H, H_{ac}), 4.73–4.69 (m, 4H, 2 × BnCH₂), 4.61 (d, *J* = 9.6 Hz, 1H, H-1), 4.37 (dd, *J* = 1.2 Hz, *J* = 12.3 Hz, 1H, H-6a), 4.16 (d, *J* = 3.3 Hz, 1H, H-4), 3.97 (dd, *J* = 1.3 Hz, *J* = 12.3 Hz, 1H, H-6b), 3.93 (t, *J* = 9.4 Hz, 1H, H-2), 3.62 (dd, *J* = 3.4 Hz, *J* = 9.2 Hz, 1H, H-3), 3.35 (s, 1H, H-5) ppm; ¹³C NMR (125 MHz, CDCl₃) $\delta = 138.6, 138.3, 135.4, 133.9, 133.0, 132.9$ (6C, 6 × C_q arom.), 132.8–124.4 (22C, arom.), 101.5 (1C, C_{ac}), 86.7 (1C, C-1), 81.5 (1C, C-3), 75.3 (2C, C-2, BnCH₂), 73.9 (1C, C-4), 71.9 (1C, BnCH₂), 70.0 (1C, C-5), 69.6 (1C, C-6) ppm; ESI-TOF-MS: *m/z* calcd for: C₃₇H₃₄NaO₅S [M + Na]⁺ 613.2019; found: 613.2054.

Phenyl 2,3-di-O-benzoyl-4,6-O-(2'-naphthyl)methylidene-1-thio-β-L-galactopyranoside (83). Compound **81** (149 mg, 0.239 mmol) was converted to **83** according to general **Method G**. The crude product was purified by silica gel chromatography (6:4 *n*-hexane/EtOAc) to give **83** (115 mg, 78%) as a white crystal. $[\alpha]_D^{25} - 111.0$ (*c* 0.10, CHCl₃); M.p.: 226–228 °C (EtOAc/*n*-hexane); *R*_f 0.44 (6:4 *n*-hexane/EtOAc); ¹H NMR (400 MHz, CDCl₃) $\delta = 7.99\text{--}7.19$ (m, 22H, arom.), 5.85 (t, *J* = 9.9 Hz, 1H, H-2), 5.61 (s, 1H, H_{ac}), 5.40 (dd, *J* = 3.4 Hz, *J* = 9.9 Hz, 1H, H-3), 4.94 (d, *J* = 9.8 Hz, 1H, H-1), 4.61 (d, *J* = 3.2 Hz, 1H, H-4), 4.43 (dd, *J* = 0.9 Hz, *J* = 12.2 Hz, 1H, H-6a), 4.06 (dd, *J* = 1.1 Hz, *J* = 12.3 Hz, 1H, H-6b), 3.66 (s, 1H, H-5) ppm; ¹³C NMR (100 MHz, CDCl₃) $\delta = 166.3, 165.0$ (2C, 2 × C_q Bz), 135.1, 133.7, 132.8, 131.2, 129.7, 129.1 (6C, 6 × C_q arom.), 133.8–124.2 (22C, arom.), 101.2 (1C, C_{ac}), 85.3 (1C, C-1), 74.1 (1C, C-3), 73.8 (1C, C-4), 69.9 (1C, C-5), 69.2 (1C, C-6), 67.2 (1C, C-2) ppm; ESI-TOF-MS: *m/z* calcd for: C₃₇H₃₀NaO₇S [M + Na]⁺ 641.1604; found: 641.1616.

Phenyl 2,3-di-O-benzyl-6-O-(2'-naphthyl)methyl-1-thio-β-L-galactopyranoside (84). Compound **82** (59 mg, 0.099 mmol) was converted to **84** according to general **Method H**. The crude product was purified by silica gel chromatography (98:2 CH₂Cl₂/acetone) to give **84** (40 mg, 68%) as a colorless syrup. $[\alpha]_D^{25} + 8.0$ (*c* 0.15, CHCl₃); *R*_f 0.35 (98:2 CH₂Cl₂/acetone); ¹H NMR (400 MHz, CDCl₃) $\delta = 7.84\text{--}7.20$ (m, 22H, arom.), 4.84–4.66 (m, 6H, NAPCH₂, 2 × BnCH₂), 4.65 (d, *J* = 9.8 Hz, 1H, H-1), 4.11 (d, *J* = 1.7 Hz, 1H, H-4), 3.87–3.79 (m, 2H,

H-6a,b), 3.76 (t, $J = 9.3$ Hz, 1H, H-2), 3.63 (t, $J = 5.7$ Hz, 1H, H-5), 3.58 (dd, $J = 3.2$ Hz, $J = 8.9$ Hz, 1H, H-3), 2.56 (s, 1H, C-4-OH) ppm; ^{13}C NMR (100 MHz, CDCl_3) $\delta = 138.3, 137.8, 135.5, 134.0, 133.4, 133.1$ (6C, $6 \times \text{C}_q$ arom.), 131.9–125.9 (22C, arom.), 87.8 (1C, C-1), 82.7 (1C, C-3), 77.2 (1C, C-5), 77.1 (1C, C-2), 75.9, 74.0, 72.3 (3C, NAPCH₂, $2 \times \text{BnCH}_2$), 69.9 (1C, C-6), 67.1 (1C, C-4) ppm; ESI-TOF-MS: m/z calcd for: $\text{C}_{37}\text{H}_{36}\text{NaO}_5\text{S} [\text{M} + \text{Na}]^+$ 615.2176; found: 615.2161.

Phenyl 2,3-di-O-benzoyl-6-O-(2'-naphthyl)methyl-1-thio-β-L-galactopyranoside (85). Compound **83** (107 mg, 0.173 mmol) was converted to **85** according to general **Method H**. The crude product was purified by silica gel chromatography (98:2 CH_2Cl_2 /acetone) to give **85** (68 mg, 64%) as a white foam. $[\alpha]_{\text{D}}^{25} -7.7.0$ (c 0.10, CHCl_3); R_f 0.32 (98:2 CH_2Cl_2 /acetone); ^1H NMR (400 MHz, CDCl_3) $\delta = 7.98\text{--}7.19$ (m, 22H, arom.), 5.82 (t, $J = 9.9$ Hz, 1H, H-2), 5.34 (dd, $J = 2.9$ Hz, $J = 9.8$ Hz, 1H, H-3), 4.96 (d, $J = 10.0$ Hz, 1H, H-1), 4.74 (s, 2H, NAPCH₂), 4.43 (s, 1H, H-4), 3.94–3.92 (m, 1H, H-5), 3.89–3.87 (m, 2H, H-6a,b), 2.86 (s, 1H, C-4-OH) ppm; ^{13}C NMR (100 MHz, CDCl_3) $\delta = 166.0, 165.4$ (2C, $2 \times \text{C}_q$ Bz), 135.2, 133.4, 133.2, 132.7, 129.6, 129.2 (6C, $6 \times \text{C}_q$ arom.), 133.5–125.8 (22C, arom.), 86.7 (1C, C-1), 77.4 (1C, C-5), 75.7 (1C, C-3), 74.0 (1C, NAPCH₂), 69.7 (1C, C-6), 68.4 (1C, C-4), 68.1 (1C, C-2) ppm; ESI-TOF-MS: m/z calcd for: $\text{C}_{37}\text{H}_{32}\text{NaO}_7\text{S} [\text{M} + \text{Na}]^+$ 643.1761; found: 643.1779.

Phenyl 2,3-di-O-benzoyl-6-O-(2'-naphthyl)methyl-4-O-(4'-nitrobenzoyl)-1-thio-β-L-glucopyranoside (86). Compound **84** (24 mg, 0.040 mmol) was converted to **86** according to general **Method K**. The crude product was purified by silica gel chromatography (7:3 *n*-hexane/EtOAc) to give **86** (18 mg, 60%) as a colorless syrup. $[\alpha]_{\text{D}}^{25} + 12.0$ (c 0.10, CHCl_3); R_f 0.63 (7:3 *n*-hexane/EtOAc); ^1H NMR (500 MHz, CDCl_3) $\delta = 7.95\text{--}7.03$ (m, 26H, arom.), 5.31 (t, $J = 9.4$ Hz, 1H, H-4), 4.95–4.52 (m, 7H, H-1, NAPCH₂, $2 \times \text{BnCH}_2$), 3.80 (t, $J = 9.1$ Hz, 1H, H-3), 3.76–3.73 (m, 1H, H-5), 3.71–3.66 (m, 2H, H-6a,b), 3.64 (t, $J = 9.3$ Hz, 1H, H-2) ppm; ^{13}C NMR (125 MHz, CDCl_3) $\delta = 163.7, 150.2$ (2C, $2 \times \text{C}_q$ *p*-NO₂-Bz), 137.9, 137.8, 135.0, 134.9, 133.5, 133.0 (6C, $6 \times \text{C}_q$ arom.), 132.2–123.2 (26C, arom.), 88.0 (1C, C-1), 83.5 (1C, C-3), 81.0 (1C, C-2), 77.0 (1C, C-5), 75.7, 75.5, 73.8 (3C, NAPCH₂, $2 \times \text{BnCH}_2$), 72.6 (1C, C-4), 70.1 (1C, C-6) ppm; ESI-TOF-MS: m/z calcd for: $\text{C}_{44}\text{H}_{39}\text{NNaO}_8\text{S} [\text{M} + \text{Na}]^+$ 764.2289; found: 764.2139.

Phenyl 2,3-di-O-benzoyl-6-O-(2'-naphthyl)methyl-4-O-(4'-nitrobenzoyl)-1-thio-β-L-glucopyranoside (87) and *Phenyl 2,3-di-O-benzoyl-6-O-(2'-naphthyl)methyl-4-deoxy-1-thio-α-D-threo-hex-4-enopyranoside (88)*. Compound **85** (40 mg, 0.063 mmol) was converted to **87** according to general **Method K**. The crude product was purified by silica gel chromatography (CH_2Cl_2) to give **87** (25 mg, 51%) as a colorless syrup and **88** (7 mg, 18%) as a colorless syrup.

Data of **87**: $[\alpha]_{\text{D}}^{25} + 20.9$ (c 0.11, CHCl_3); R_f 0.55 (CH_2Cl_2); ^1H NMR (500 MHz, CDCl_3) $\delta = 7.96\text{--}7.26$ (m, 26H, arom.), 5.85 (t, $J = 9.4$ Hz, 1H, H-3), 5.56 (t, $J = 9.7$ Hz, 1H, H-4), 5.51 (t, $J = 9.7$ Hz, 1H, H-2), 5.05 (d, $J = 10.0$ Hz, 1H, H-1), 4.64 (s, 2H, NAPCH₂), 4.07–4.05 (m, 1H, H-5), 3.84–3.78 (m, 2H, H-6a,b) ppm; ^{13}C NMR (125 MHz, CDCl_3) $\delta = 165.9, 165.2, 163.7, 150.4$ (4C, $2 \times \text{C}_q$ Bz, $2 \times \text{C}_q$ *p*-NO₂-Bz), 134.9, 134.4, 133.0, 132.1, 129.3, 128.8 (6C, $6 \times \text{C}_q$ arom.), 133.5–123.3 (26C, arom.), 86.6 (1C, C-1), 77.4 (1C, C-5), 74.4 (1C, C-3), 73.9 (1C, NAPCH₂), 71.3 (1C, C-4), 70.6 (1C, C-2), 69.5 (1C, C-6) ppm; ESI-TOF-MS: m/z calcd for: $\text{C}_{44}\text{H}_{35}\text{NNaO}_{10}\text{S} [\text{M} + \text{Na}]^+$ 792.1874; found: 792.1800.

Data of **88**: $[\alpha]_{\text{D}}^{25} + 49.5$ (c 0.62, CHCl_3); R_f 0.41 (CH_2Cl_2); ^1H NMR (500 MHz, CDCl_3) $\delta = 8.20\text{--}7.26$ (m, 22H, arom.), 5.86 (s, 1H, H-1), 5.75 (s, 1H, H-2), 5.54 (s, 2H, H-3, H-4), 4.78 (dd, $J = 11.8$ Hz, $J = 30.2$ Hz, 2H, NAPCH₂), 4.18 (d, $J = 13.3$ Hz, 1H, H-6a), 4.10 (d, $J = 13.1$ Hz, 1H, H-6b) ppm; ^{13}C NMR (125 MHz, CDCl_3) $\delta = 165.6, 165.5$ (2C, $2 \times \text{C}_q$ Bz), 152.0 (1C, C-5), 135.9, 135.3, 134.5, 129.9, 129.2 (6C, $6 \times \text{C}_q$ arom.), 133.7–126.0 (22C, arom.), 97.3 (1C, C-4), 84.0 (1C, C-1), 72.5 (1C, NAPCH₂), 70.0 (1C, C-2), 69.6 (1C, C-6), 64.9 (1C, C-3) ppm; ESI-TOF-MS: m/z calcd for: $\text{C}_{37}\text{H}_{30}\text{NaO}_6\text{S} [\text{M} + \text{Na}]^+$ 625.1655; found: 625.1632.

4. Conclusions

We have successfully developed an efficient synthetic route for the preparation of four rare L-hexoses (L-gulose, L-galactose, L-allose, and L-glucose) in the form of orthogonally protected thioglycosides, starting from the cheap D-mannose, using the most readily avail-

able chemicals and most cost-effective transformations possible. The preparation of the 5,6-unsaturated derivatives, required for the C-5 epimerization, was investigated systematically in the presence of ether and ester protecting groups. We have found that the outcome of the elimination reactions is strongly dependent on both the protecting group pattern, the sugar configuration, and the reagent applied. For the fully ether protected derivative, elimination with NaH reagent led to the best yields. AgF-induced dehydrohalogenation proceeded efficiently from ester-bearing compounds, however, in the case of C-3 ester group, a glycal by-product has also been formed due to elimination and subsequent allylic rearrangement. The only example for such an intriguing side reaction has previously been observed in photoinitiated thiol-ene reaction of 2,3-unsaturated α -thioglycosides [38]. In DBU-induced reactions, significant amounts of amidinium salt by-products were formed in all cases, regardless of the type and configuration of the protecting groups. C-5 epimerization could be performed with good stereoselectivity for all derivatives, but the yields were significantly higher for ester-protected derivatives than for ether protected ones. Oxidation-reduction-based C-4 epimerization of vicinal *trans* diols to vicinal *cis* diols was performed with good stereoselectivity in the presence of an ether protecting group adjacent to the keto functionality. The same method yielded vicinal *trans* diol in the presence of an ester group adjacent to the oxo group, which was exploited during the D-mannose to D-altrose conversion. The Mitsunobu inversion proved to be suitable for the preparation of equatorial *trans* diols, but an undesired elimination side reaction was also observed in the presence of an adjacent ester group. All designed L-hexoses were successfully prepared in 9–15 steps (total yields for L-gulose: 21–23%; for L-galactose: 6–8%; for L-allose: 6–8%; for L-glucose: 2–3%) as thioglycosides suitable for the synthesis of oligosaccharides, which can facilitate the synthesis of biologically active molecules.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/molecules27113422/s1>. 1D and 2D NMR spectra of the synthesized compounds and the X-ray structure analysis of compound **83**. Reference [100] are cited in the Supplementat Materials.

Author Contributions: Conceptualization, M.H. and A.B.; investigation, F.D., I.B. and M.H.; writing—original draft preparation, F.D., M.H. and A.B.; writing—review and editing, F.D., M.H. and A.B.; supervision M.H. and A.B.; funding acquisition, M.H. and A.B. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Premium Postdoctoral Program of HAS (grant no. PPD 461038, M.H.), the National Research and Development and Innovation Office of Hungary (grant no. K 132870, A.B.; grant no. FK 137924 M.H.), and the EU and co-financed by the European Regional Development Fund under the project GINOP-2.3.4-15-2020-00008.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The authors thank for Attila Bényei (University of Debrecen) for collecting X-ray data and Mariann Varga and Márta Bodza for excellent technical assistance.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: For availability of samples of compounds contact the corresponding author.

References

1. De Lederkremer, R.M.; Gallo-Rodriguez, C. Naturally occurring monosaccharides: Properties and synthesis. *Adv. Carbohydr. Chem. Biochem.* **2004**, *59*, 9–67.
2. Draget, K.I.; Taylor, C. Chemical, physical and biological properties of alginates and their biomedical implications. *Food Hydrocoll.* **2011**, *25*, 251–256. [[CrossRef](#)]
3. Haug, A.; Larsen, B.; Smidsrod, O. Studies on the sequence of uronic acid residues in alginic acid. *Acta Chem. Scand.* **1967**, *21*, 691–704. [[CrossRef](#)]

4. Aarstad, O.A.; Tøndervik, A.; Sletta, H.; Skjåk-Bræk, G. Alginate Sequencing: An Analysis of Block Distribution in Alginates Using Specific Alginate Degrading Enzymes. *Biomacromolecules* **2012**, *13*, 106–116. [[CrossRef](#)]
5. Goh, C.H.; Heng, P.W.S.; Chan, L.W. Alginates as a useful natural polymer for microencapsulation and therapeutic applications. *Carbohydr. Polym.* **2012**, *88*, 1–12. [[CrossRef](#)]
6. Kloareg, B.; Quatrano, R.S. Structure of the Cell Walls of Marine Algae and Ecophysiological Functions of the Matrix Polysaccharides. *Oceanogr. Mar. Biol. Annu. Rev.* **1988**, *26*, 259–315.
7. Umezawa, H. Natural and artificial bleomycins: Chemistry and antitumour activities. *Pure Appl. Chem.* **1971**, *28*, 665–680. [[CrossRef](#)]
8. Boger, D.L.; Teramoto, S.; Zhou, J. Key Synthetic Analogs of Bleomycin A2 That Directly Address the Effect and Role of the Disaccharide: Demannosylbleomycin A2 and alpha-D-Mannopyranosyl deglycobleomycin A2. *J. Am. Chem. Soc.* **1995**, *117*, 7344–7356. [[CrossRef](#)]
9. Yu, Z.; Schmaltz, R.M.; Bozeman, T.C.; Paul, R.; Rishel, M.J.; Tsosie, K.S.; Hecht, S.M. Selective Tumor Cell Targeting by the Disaccharide Moiety of Bleomycin. *J. Am. Chem. Soc.* **2013**, *135*, 2883–2886. [[CrossRef](#)]
10. Sasamori, H.; Reddy, K.S.; Kirkup, M.P.; Shabanowitz, J.; Lynn, D.G.; Hecht, S.M.; Woode, K.A.; Bryan, R.F.; Campbell, J.; Lynn, W.S.; et al. New cytotoxic principles from *Datisca glomerata*. *J. Chem. Soc. Perkin Trans.* **1983**, *1*, 1333–1347. [[CrossRef](#)]
11. Ridley, B.L.; O'Neill, M.A.; Mohnen, D. Pectins: Structure, biosynthesis, and oligogalacturonide-related signaling. *Phytochemistry* **2001**, *57*, 929–967. [[CrossRef](#)]
12. Li, Y.S.; Matsunaga, K.; Ishibashi, M.; Ohizumi, Y. Littoralisone, a Novel Neuritogenic Iridolactone Having an Unprecedented Heptacyclic Skeleton Including Four- and Nine-Membered Rings Consisting of Glucose from *Verbena littoralis*. *J. Org. Chem.* **2001**, *66*, 2165–2167. [[CrossRef](#)] [[PubMed](#)]
13. Mangion, I.K.; MacMillan, D.W.C. Total Synthesis of Brasoside and Littoralisone. *J. Am. Chem. Soc.* **2005**, *127*, 3696–3697. [[CrossRef](#)] [[PubMed](#)]
14. Kim, J.W.; Adachi, H.; Shin-ya, K.; Hayakawa, Y.; Seto, H.J. Apoptolidin, a New Apoptosis Inducer in Transformed Cells from *Nocardiaopsis* sp. *J. Antibiot.* **1997**, *50*, 628–630. [[CrossRef](#)]
15. Hayakawa, Y.; Kim, J.W.; Adachi, H.; Shin-ya, K.; Fujita, K.; Seto, H. Structure of Apoptolidin, a Specific Apoptosis Inducer in Transformed Cells. *J. Am. Chem. Soc.* **1998**, *120*, 3524–3525. [[CrossRef](#)]
16. Daniel, P.T.; Koert, U.; Schuppan, J. Apoptolidin: Induction of Apoptosis by a Natural Product. *Angew. Chem. Int. Ed.* **2006**, *45*, 872–893. [[CrossRef](#)]
17. Lever, R.; Mulloy, B.; Page, C.P. (Eds.) *Heparin—A Century of Progress*; Springer: Berlin/Heidelberg, Germany, 2012.
18. Casu, B.; Lindahl, U. Structure and biological interactions of heparin and heparan sulfate. *Adv. Carbohydr. Chem. Biochem.* **2001**, *57*, 159–206.
19. Chhabra, M.; Doherty, G.G.; See, N.W.; Gandhi, N.S.; Ferro, V. From Cancer to COVID-19: A Perspective on Targeting Heparan Sulfate-Protein Interactions. *Chem. Rec.* **2021**, *21*, 3087–3101. [[CrossRef](#)]
20. Frihed, T.G.; Bols, M.; Pedersen, C.M. Synthesis of L-Hexoses. *Chem. Rev.* **2015**, *115*, 3615–3676. [[CrossRef](#)]
21. D'Alonzo, D.; Guaragna, A.; Palumbo, G. Recent Advances in Monosaccharide Synthesis: A Journey into L-Hexose World. *Curr. Org. Chem.* **2009**, *13*, 71–98. [[CrossRef](#)]
22. Zulueta, M.M.L.; Zhong, Y.-Q.; Hung, S.-C. Synthesis of L-hexoses and their related biomolecules. *Chem. Commun.* **2013**, *49*, 3275–3287. [[CrossRef](#)] [[PubMed](#)]
23. Kulkarni, S.S.; Chi, F.C.; Hung, S.C. Biologically Potent L-Hexoses and 6-Deoxy-L-Hexoses: Their Syntheses and Applications. *J. Chin. Chem. Soc.* **2004**, *51*, 1193–1200. [[CrossRef](#)]
24. Paul, A.; Kulkarni, S.S. Synthesis of L-Hexoses: An Update. *Chem. Rec.* **2021**, *21*, 3224–3237. [[CrossRef](#)] [[PubMed](#)]
25. Takahashi, H.; Miyama, N.; Mitsuzuka, H.; Ikegami, S. Synthesis of L-Pyranosides from 5-Enopyranosides by Diastereoselective Hydroboration/Oxidation. *Synthesis* **2004**, *18*, 2991–2994. [[CrossRef](#)]
26. Lopatkiewicz, G.; Mlynarski, J. Synthesis of L-Pyranosides by Hydroboration of Hex-5-enopyranosides Revisited. *J. Org. Chem.* **2016**, *81*, 7545–7556. [[CrossRef](#)] [[PubMed](#)]
27. Kovár, J. Improvements for the preparation of L-idose from D-glucose. *Can. J. Chem.* **1970**, *48*, 2383–2385. [[CrossRef](#)]
28. Evans, M.E.; Parrish, F.W. A simple synthesis of L-gulose. *Carbohydr. Res.* **1973**, *28*, 359–364. [[CrossRef](#)]
29. Lee, J.-C.; Lu, X.-A.; Kulkarni, S.S.; Wen, Y.-S.; Hung, S.-C. Synthesis of Heparin Oligosaccharides. *J. Am. Chem. Soc.* **2004**, *126*, 476–477. [[CrossRef](#)]
30. Boulineau, F.P.; Wei, A. Mirror-Image Carbohydrates: Synthesis of the Unnatural Enantiomer of a Blood Group Trisaccharide. *J. Org. Chem.* **2004**, *69*, 3391–3399. [[CrossRef](#)]
31. Takahashi, H.; Hitomi, Y.; Iwai, Y.; Ikegami, S. A Novel and Practical Synthesis of L-Hexoses from D-Glycono-1,5-lactones. *J. Am. Chem. Soc.* **2000**, *122*, 2995–3000. [[CrossRef](#)]
32. Chiba, T.; Sinay, P. Application of a radical reaction to the synthesis of L-iduronic acid derivatives from D-glucuronic acid analogues. *Carbohydr. Res.* **1986**, *151*, 379–389. [[CrossRef](#)]
33. Medakovic, D. An efficient synthesis of methyl 1,2,3,4-tetra-O-acetyl-β-L-idopyranuronate. *Carbohydr. Res.* **1994**, *253*, 299–300. [[CrossRef](#)]
34. Yu, H.N.; Furukawa, J.; Ikeda, T.; Wong, C.-H. Novel Efficient Routes to Heparin Monosaccharides and Disaccharides Achieved via Regio- and Stereoselective Glycosidation. *Org. Lett.* **2004**, *6*, 723–726. [[CrossRef](#)] [[PubMed](#)]

35. Takahashi, H.; Shida, T.; Hitomi, Y.; Iwai, Y.; Miyama, N.; Nishiyama, K.; Sawada, D.; Ikegami, S. Divergent Synthesis of L-Sugars and L-Iminosugars from D-Sugars. *Chem. Eur. J.* **2006**, *12*, 5868–5877. [[CrossRef](#)]
36. Weymouth-Wilson, A.C.; Clarkson, R.A.; Jones, N.A.; Best, D.; Wilson, F.X.; Pino-González, M.-S.; Fleet, G.W.J. Large scale synthesis of the acetonides of L-glucuronolactone and of L-glucose: Easy access to L-sugar chiroins. *Tetrahedron Lett.* **2009**, *50*, 6307–6310. [[CrossRef](#)]
37. Herczeg, M.; Lázár, L.; Bereczky, Z.; Kövér, K.E.; Timári, I.; Kappelmayer, J.; Lipták, A.; Antus, S.; Borbás, A. Synthesis and Anticoagulant Activity of Bioisosteric Sulfonic-Acid Analogues of the Antithrombin-Binding Pentasaccharide Domain of Heparin. *Chem. Eur. J.* **2012**, *18*, 10643–10652. [[CrossRef](#)]
38. Lubineau, A.; Gavard, O.; Alais, J.; Bonnaffé, D. New accesses to L-iduronyl synthons. *Tetrahedron Lett.* **2000**, *41*, 307–311. [[CrossRef](#)]
39. Dondoni, A.; Marra, A.; Massi, A. Carbohydrate Homologation by the Use of 2-(Trimethylsilyl)thiazole. Preparative Scale Synthesis of Rare Sugars: L-Gulose, L-Idose, and the Disaccharide Subunit of Bleomycin A2. *J. Org. Chem.* **1997**, *62*, 6261–6267. [[CrossRef](#)]
40. Timmer, M.S.M.; Adibekian, A.; Seeberger, P.H. Short *De Novo* Synthesis of Fully Functionalized Uronic Acid Monosaccharides. *Angew. Chem. Int. Ed.* **2005**, *44*, 7605–7607. [[CrossRef](#)]
41. Hansen, S.U.; Baráth, M.; Salameh, B.A.B.; Pritchard, R.G.; Stimpson, W.; Gardiner, J.M.; Jayson, G.C. Scalable Synthesis of L-Iduronic Acid Derivatives via Stereocontrolled Cyanohydrin Reaction for Synthesis of Heparin-Related Disaccharides. *Org. Lett.* **2009**, *11*, 4528–4531. [[CrossRef](#)]
42. Walke, G.; Kasdekar, N.; Sutar, Y.; Hotha, S. Silver-assisted gold-catalyzed formal synthesis of the anticoagulant Fondaparinux pentasaccharide. *Commun. Chem.* **2021**, *4*, 15. [[CrossRef](#)]
43. Honzumi, M.; Taniguchi, T.; Ogasawara, K. A New Convergent Route to Aldohexoses from a Common Chiral Building Block. *Org. Lett.* **2001**, *3*, 1355–1358. [[CrossRef](#)] [[PubMed](#)]
44. Ermolenko, L.; Sasaki, N.A. Diastereoselective Synthesis of All Eight L-Hexoses from L-Ascorbic Acid. *J. Org. Chem.* **2006**, *71*, 693–703. [[CrossRef](#)] [[PubMed](#)]
45. Harris, J.M.; Keranen, M.D.; O'Doherty, G.A. Syntheses of D- and L-Mannose, Gulose, and Talose via Diastereoselective and Enantioselective Dihydroxylation Reactions. *J. Org. Chem.* **1999**, *64*, 2982–2983. [[CrossRef](#)]
46. Harris, J.M.; Keränen, M.D.; Nguyen, H.; Young, V.G.; O'Doherty, G.A. Syntheses of four D- and L-hexoses via diastereoselective and enantioselective dihydroxylation reactions. *Carbohydr. Res.* **2000**, *328*, 17–36. [[CrossRef](#)]
47. Ahmed, M.M.; O'Doherty, G.A. De Novo Asymmetric Syntheses of D- and L-Talose via an Iterative Dihydroxylation of Dienoates. *J. Org. Chem.* **2005**, *70*, 10576–10578. [[CrossRef](#)]
48. Northrup, A.B.; MacMillan, D.W.C. Two-Step Synthesis of Carbohydrates by Selective Aldol Reactions. *Science* **2004**, *305*, 1752–1755. [[CrossRef](#)]
49. Guaragna, A.; D'Alonzo, D.; Paoletta, C.; Napolitano, C.; Palumbo, G. Highly Stereoselective de Novo Synthesis of L-Hexoses. *J. Org. Chem.* **2010**, *75*, 3558–3568. [[CrossRef](#)]
50. Mlynarski, J.; Gut, B. Organocatalytic synthesis of carbohydrates. *Chem. Soc. Rev.* **2012**, *41*, 587–596. [[CrossRef](#)]
51. Katano, K.; Chang, P.-I.; Millar, A.; Pozsgay, V.; Minster, D.K.; Ohgi, T.; Hecht, S.M. Synthesis of the carbohydrate moiety of bleomycin. 1,3,4,6-Tetra-O-substituted L-gulose derivatives. *J. Org. Chem.* **1985**, *50*, 5807–5815. [[CrossRef](#)]
52. Vlahov, I.R.; Linhardt, R.J. Regioselective synthesis of derivatives of L-idopyranuronic acid: A key constituent of glycosaminoglycans. *Tetrahedron Lett.* **1995**, *36*, 8379–8382. [[CrossRef](#)]
53. Hajkó, J.; Lipták, A.; Pozsgay, V. Synthesis of L-glucose from D-gulonono-1,4-lactone. *Carbohydr. Res.* **1999**, *321*, 116–120. [[CrossRef](#)]
54. Ke, W.; Whitfield, D.M.; Gill, M.; Larocque, S.; Yu, S.H. A short route to L-iduronic acid building blocks for the syntheses of heparin-like disaccharides. *Tetrahedron Lett.* **2003**, *44*, 7767–7770. [[CrossRef](#)]
55. Martinez, R.F.; Liu, Z.; Glawar, A.F.G.; Yoshihara, A.; Izumori, K.; Fleet, G.W.J.; Jenkinson, S.F. Short and Sweet: D-Glucose to L-Glucose and L-Glucuronic Acid. *Angew. Chem. Int. Ed.* **2014**, *53*, 1160–1162. [[CrossRef](#)]
56. Valverde, P.; Vendeville, J.-B.; Hollingsworth, K.; Matthey, A.P.; Keenan, T.; Chidwick, H.; Ledru, H.; Huonnic, K.; Huang, K.; Light, M.E.; et al. Chemoenzymatic synthesis of 3-deoxy-3-fluoro-L-fucose and its enzymatic incorporation into glycoconjugates. *Chem. Commun.* **2020**, *56*, 6408–6411. [[CrossRef](#)] [[PubMed](#)]
57. Wang, Y.; Carder, H.M.; Wendlandt, A.E. Synthesis of rare sugar isomers through site-selective epimerization. *Nature* **2020**, *578*, 403–408. [[CrossRef](#)] [[PubMed](#)]
58. Dimakos, V.; Su, H.Y.; Garrett, G.E.; Taylor, M.S. Site-Selective and Stereoselective C–H Alkylations of Carbohydrates via Combined Diarylborinic Acid and Photoredox Catalysis. *J. Am. Chem. Soc.* **2019**, *141*, 5149–5153. [[CrossRef](#)] [[PubMed](#)]
59. Frihed, T.G.; Heuckendorff, M.; Pedersen, C.M.; Bols, M. Easy Access to L-Mannosides and L-Galactosides by Using C-H Activation of the Corresponding 6-Deoxysugars. *Angew. Chem. Int. Ed.* **2012**, *51*, 12285–12288. [[CrossRef](#)]
60. Frihed, T.G.; Pedersen, C.M.; Bols, M. Synthesis of All Eight L-Glycopyranosyl Donors Using C-H Activation. *Angew. Chem. Int. Ed.* **2014**, *53*, 13889–13893. [[CrossRef](#)]
61. Izumori, K. Izumoring: A strategy for bioproduction of all hexoses. *J. Biotechnol.* **2006**, *124*, 717–722. [[CrossRef](#)]
62. Dean, S.M.; Greenberg, W.A.; Wong, C.H. Recent Advances in Aldolase-Catalyzed Asymmetric Synthesis. *Adv. Synth. Catal.* **2007**, *349*, 1308–1320. [[CrossRef](#)]
63. Sanapala, S.R.; Kulkarni, S.S. From L-Rhamnose to Rare 6-Deoxy-L-Hexoses. *Org. Lett.* **2016**, *18*, 3790–3793. [[CrossRef](#)] [[PubMed](#)]

64. Frihed, T.G.; Pedersen, C.M.; Bols, M. Synthesis of All Eight Stereoisomeric 6-Deoxy-L-hexopyranosyl Donors—Trends in Using Stereoselective Reductions or Mitsunobu Epimerizations. *Eur. J. Org. Chem.* **2014**, *2014*, 7924–7939. [[CrossRef](#)]
65. Herczeg, M.; Demeter, F.; Balogh, T.; Kelemen, V.; Borbás, A. Rapid Synthesis of L-Idosyl Glycosyl Donors from α -Thioglucosides for the Preparation of Heparin Disaccharides. *Eur. J. Org. Chem.* **2018**, *2018*, 3312–3316. [[CrossRef](#)]
66. Demeter, F.; Veres, F.; Herczeg, M.; Borbás, A. Short Synthesis of Idraparinux by Applying a 2-O-Methyl-4,6-O-arylmethylene Thioidoside as a 1,2-*trans*- α -Selective Glycosyl Donor. *Eur. J. Org. Chem.* **2018**, *2018*, 6901–6912. [[CrossRef](#)]
67. Boger, D.L.; Honda, T. Total Synthesis of Bleomycin A2 and Related Agents. 4. Synthesis of the Disaccharide Subunit 2-O-(3-O-Carbamoyl- α -D-mannopyranosyl)-L-gulopyranose and Completion of the Total Synthesis of Bleomycin A2. *J. Am. Chem. Soc.* **1994**, *116*, 5647–5656. [[CrossRef](#)]
68. Chiba, T.; Jacquinet, J.-C.; Sinay, P.; Petitou, M.; Choay, J. Chemical synthesis of L-iduronic acid-containing disaccharidic fragments of heparin. *Carbohydr. Res.* **1988**, *174*, 253–264. [[CrossRef](#)]
69. Lopatkiewicz, G.; Buda, S.; Mlynarski, J. Application of the EF and GH Fragments to the Synthesis of Idraparinux. *J. Org. Chem.* **2017**, *82*, 12701–12714. [[CrossRef](#)]
70. Chrétien, F. A Convenient Preparation of Hex-5,6-enopyranosides. *Synth. Commun.* **1989**, *19*, 1015–1024. [[CrossRef](#)]
71. O'Brien, J.L.; Tosin, M.; Murphy, P.V. Novel Synthesis of the Glycosidase Inhibitor Deoxymannojirimycin and of a Synthetic Precursor D-lyxo-Hexos-5-ulose. *Org. Lett.* **2001**, *3*, 3353–3356. [[CrossRef](#)]
72. Sakairi, N.; Hayashida, M.; Kuzuhara, H. Synthesis of a new antimicrobial aminoglycoside employing maltose as a key starting material. *Tetrahedron Lett.* **1987**, *28*, 2871–2874. [[CrossRef](#)]
73. Shimawaki, K.; Fujisawa, Y.; Sato, F.; Fujitani, N.; Kurogochi, M.; Hoshi, H.; Hinou, H.; Nishimura, S.-I. Highly Efficient and Versatile Synthesis of Proteoglycan Core Structures from 1,6-Anhydro- β -lactose as a Key Starting Material. *Angew. Chem. Int. Ed. Engl.* **2007**, *119*, 3134–3139. [[CrossRef](#)]
74. Pearce, A.J.; Chevalier, R.; Mallet, J.-M.; Sinay, P. Cascade Rearrangements of Polyunsaturated Sugars: A Novel Approach to the Synthesis of Oligosaccharide Mimetics. *Eur. J. Org. Chem.* **2000**, *2000*, 2203–2206. [[CrossRef](#)]
75. Rochepeau-Jobron, L.; Jacquinet, J.-C. Diastereoselective hydroboration of substituted *exo*-glucals revisited. A convenient route for the preparation of L-iduronic acid derivatives. *Carbohydr. Res.* **1997**, *303*, 395–406. [[CrossRef](#)]
76. Hinou, H.; Kurosawa, H.; Matsuoka, K.; Terunuma, D.; Kuzuhara, H. Novel synthesis of L-iduronic acid using trehalose as the disaccharidic starting material. *Tetrahedron Lett.* **1999**, *40*, 1501–1504. [[CrossRef](#)]
77. Lee, J.-C.; Chang, S.-W.; Liao, C.-C.; Chi, F.-C.; Chen, C.-S.; Wen, Y.-S.; Wang, C.-C.; Kulkarni, S.S.; Puranik, R.; Liu, Y.-H.; et al. From D-Glucose to Biologically Potent L-Hexose Derivatives: Synthesis of α -L-Iduronidase Fluorogenic Detector and the Disaccharide Moieties of Bleomycin A2 and Heparan Sulfate. *Chem. Eur. J.* **2004**, *10*, 399–415. [[CrossRef](#)]
78. Demeter, F.; Chang, M.D.-T.; Lee, Y.-C.; Borbás, A.; Herczeg, M. An Efficient Synthesis of the Pentasaccharide Repeating Unit of *Pseudomonas aeruginosa* Psl Exopolysaccharide. *Synlett* **2020**, *31*, 469–474. [[CrossRef](#)]
79. Wang, Z.; Chinoy, Z.S.; Ambre, S.G.; Peng, W.; McBride, R.; de Vries, R.P.; Glushka, J.; Paulson, J.C.; Boons, G.-J. A General Strategy for the Chemoenzymatic Synthesis of Asymmetrically Branched N-Glycans. *Science* **2013**, *341*, 379–383. [[CrossRef](#)]
80. Baidya, M.; Mayr, H. Nucleophilicities and carbon basicities of DBU and DBN. *Chem. Commun.* **2008**, *15*, 1792–1794. [[CrossRef](#)]
81. Maji, B.; Breugst, M.; Mayr, H. N-Heterocyclic Carbenes: Organocatalysts with Moderate Nucleophilicity but Extraordinarily High Lewis Basicity. *Angew. Chem. Int. Ed. Engl.* **2011**, *50*, 6915–6919. [[CrossRef](#)]
82. Li, Z.; Ji, P.; Cheng, J.-P. Brønsted Basicities and Nucleophilicities of N-Heterocyclic Olefins in Solution: N-Heterocyclic Carbene versus N-Heterocyclic Olefin. Which Is More Basic, and Which Is More Nucleophilic? *J. Org. Chem.* **2021**, *86*, 2974–2985. [[CrossRef](#)] [[PubMed](#)]
83. Lammers, H.; Cohen-Fernandes, P.; Habraken, C.L. Nucleophilic behaviour of DBU and DBN in reactions with 4-halo-3,5-dimethyl-1-nitro-1H-pyrazoles. *Tetrahedron* **1994**, *50*, 865–870. [[CrossRef](#)]
84. Johnson, M.G.; Foglesong, R.J. Nucleophilic behavior of DBU in a conjugate addition reaction. *Tetrahedron Lett.* **1997**, *38*, 7003–7006. [[CrossRef](#)]
85. Németh, A.G.; Szabó, R.; Domján, A.; Keserű, G.M.; Ábrányi-Balogh, P. Chromatography-Free Multicomponent Synthesis of Thioureas Enabled by Aqueous Solution of Elemental Sulfur. *ChemistryOpen* **2021**, *10*, 16–27.
86. Kaur, N.; Chopra, H.K. Synthesis and applications of carbohydrate based chiral ionic liquids as chiral recognition agents and organocatalysts. *J. Mol. Liq.* **2020**, *298*, 111994. [[CrossRef](#)]
87. Thomas, M.; Montenegro, D.; Castaño, A.; Friedman, L.; Leb, J.; Huang, M.L.; Rothman, L.; Lee, H.; Capodiferro, C.; Ambinder, D.; et al. Polycations. 17. Synthesis and properties of polycationic derivatives of carbohydrates. *Carbohydr. Res.* **2009**, *344*, 1620–1627.
88. Engel, R.; Ghani, I.; Montenegro, D.; Thomas, M.; Klaritch-Vrana, B.; Castaño, A.; Friedman, L.; Leb, J.; Rothman, L.; Lee, H.; et al. Polycationic Glycosides. *Molecules* **2011**, *16*, 1508–1518. [[CrossRef](#)]
89. Levene, P.A. The Pentacetate of α -Mannose. *J. Biol. Chem.* **1924**, *59*, 141–144.
90. Maity, S.K.; Dutta, S.K.; Banerjee, A.K.; Achari, B.; Singh, M. Design and synthesis of mannose analogues as inhibitors of α -mannosidase. *Tetrahedron* **1994**, *50*, 6965–6974. [[CrossRef](#)]
91. Li, T.; Huang, M.; Liu, L.; Wang, S.; Moremen, K.W.; Boons, G.-J. Divergent Chemoenzymatic Synthesis of Asymmetrical-Core-Fucosylated and Core-Unmodified N-Glycans. *Chem. Eur. J.* **2016**, *22*, 18742–18746. [[CrossRef](#)]

92. Kelemen, V.; Csávás, M.; Hotzi, J.; Herczeg, M.; Poonam Rathi, B.; Herczegh, P.; Jain, N.; Borbás, A. Photoinitiated Thiol–Ene Reactions of Various 2,3-Unsaturated *O*-, *C*-, *S*- and *N*-Glycosides—Scope and Limitations Study. *Chem. Asian J.* **2020**, *15*, 876–891. [[CrossRef](#)] [[PubMed](#)]
93. Brown, H.; Krishnamurthy, S. Lithium tri-*sec*-butylborohydride. New reagent for the reduction of cyclic and bicyclic ketones with super stereoselectivity. Remarkably simple and practical procedure for the conversion of ketones to alcohols in exceptionally high stereochemical purity. *J. Am. Chem. Soc.* **1972**, *94*, 7159–7161. [[CrossRef](#)]
94. Oshitari, T.; Shibasaki, M.; Yoshizawa, T.; Tomita, M.; Takao, K.-I.; Kobayashi, S. Synthesis of 2-*O*-(3-*O*-carbamoyl- α -D-mannopyranosyl)-L-gulopyranose: Sugar moiety of antitumor antibiotic bleomycin. *Tetrahedron* **1997**, *53*, 10993–11006. [[CrossRef](#)]
95. Cram, D.J.; Kopecky, K.R. Studies in Stereochemistry. XXX. Models for Steric Control of Asymmetric Induction. *J. Am. Chem. Soc.* **1959**, *81*, 2748–2755. [[CrossRef](#)]
96. Chang, C.-W.T.; Hui, Y.; Elchert, B. Studies of the stereoselective reduction of ketosugar (hexosulose). *Tetrahedron Lett.* **2001**, *42*, 7019–7023. [[CrossRef](#)]
97. Lichtenthaler, F.W.; Schneider-Adams, T. 3,4,6-Tri-*O*-benzyl- α -D-arabino-hexopyranos-2-ulosyl Bromide: A Versatile Glycosyl Donor for the Efficient Generation of β -D-Mannopyranosidic Linkages. *J. Org. Chem.* **1994**, *59*, 6728–6734. [[CrossRef](#)]
98. Alfredsson, G.; Garegg, P.J. The Benzoylation of Some Glycosides with a Mixture of Benzoic Acid, Triphenylphosphine, and Diethyl Azodicarboxylate. *Acta Chem. Scand.* **1973**, *27*, 724–726. [[CrossRef](#)]
99. Piacenza, L.P.L.; Pegel, K.H.; Liang, M.; Waight, E.S.; Weeks, C.M.; Gorst-Allman, C.P. A new atisane diterpene: Ent-16 α -hydroxyatis-13-en-3-one from *Androstachys johnsonii* prain. *J. Chem. Soc. Perkin Trans.* **1985**, *1*, 703–709. [[CrossRef](#)]
100. Westrip, S.P. publCIF: Software for editing, validating and formatting crystallographic information files. *J. Apply. Cryst.* **2010**, *43*, 920–925.